1 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399155]  
2019- 1091, Version 5 MD Anderson IND Sponsor Cover Sheet  
Protocol ID  2019 -1091  
Protocol Title  Phase I/II Trial of BINTRAFUSP ALFA (M7824) and Pi[INVESTIGATOR_399156]  I/II 
Protocol Version  5 
Version Date  09/26/202 3 
Protocol PI  [INVESTIGATOR_399157], MD, PhD  
Department  Melanoma Medical Oncology  
Investigational 
Products  BINTRAFUSP ALFA (M7824)  and Pi[INVESTIGATOR_399158] #  151629  
Proprietary Information of MD Anderson
2 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
  
   
 
    
                    PROTOCOL  
TITLE:  Phase I/II Trial of BINTRAFUSP ALFA (M7824) and Pi[INVESTIGATOR_399160]:  MDACC: 2019 -1091  
  
 
VERSION  NUMBER:  Version 5 
 
PROTOCOL  DATE:  [ADDRESS_503133]  PRODUCTS:  BINTRAFUSP ALFA (M7824)  
Pi[INVESTIGATOR_399161]:  Hussein Tawbi, MD, PhD  
Associate [CONTACT_399292]: [EMAIL_7634]  
 Jing Li, MD, PhD Associate [CONTACT_399293] E-mail:  [EMAIL_7635]  
 
  
Proprietary Information of MD Anderson
3 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
 Co-INVESTIGATOR:  
 
  Mehmet Altan, M.D.  
Assistant [CONTACT_399294]/Head and Neck Medicine  
E-mail:  [EMAIL_7636]  
 Rashmi Murthy, MD 
Assistant [CONTACT_399295]: rm [EMAIL_7637] 
  Jeffrey S. Wefel, PhD  
Associate [CONTACT_399296] E-mail:  [EMAIL_7638]  
 William A. Murphy, Jr. M.D. [CONTACT_399297]: [EMAIL_7639]  
 
                   SUPPORTING COMPANY :                      EMD  SERENO , INC 
 
                    
 
 
         
 
        
Proprietary Information of MD Anderson
4 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
 TABLE OF CONTENTS  
TRIA L SUMMARY  ........................................................................................................................ 7  
1.0  Background information  ..................................................................................................... 10 
1.1 Disease Background:  Brain Metastases  ........................................................................ 10 
Disease Background: Radiation Therapy for Brain Metastases  ................................................. 10 
1.2  Disease Background:  Brain Metastases and Melanoma  .................................................... 12 
1.3  Disease Background:  Brain Metastases and breast cancer ................................................. 14 
1.4 Disease Background:  Brain Metastases and Lung Cancer  .................................................. 15 
1.5  PI[INVESTIGATOR_399162]  .................................................................................................................... 16 
2.0  RATIONALE For the Study  .......................................................................................... 17 
3.0  Study design  .......................................................................................................................... 18 
4.0  OBJECTIVES  ........................................................................................................................ 20 
4.1 Primary Objective  ........................................................................................................ 20 
4.1.1  Phase I Primary Objective .......................................................................................... 20 
4.1.2  Phase II Primary Objective ......................................................................................... 20 
4.2 Secondary Objectives  ................................................................................................... 21 
4.3 Exploratory Objective  ................................................................................................. 21 
5.0 Patients  .................................................................................................................................. 21 
5.1 Inclusion Criteria  ......................................................................................................... 22 
5.2 Exclusion Criteria  ........................................................................................................ 24 
6.0 Trial Treatment  ...................................................................................................................... 26 
6.1 BINTRAFUSP ALFA (M7824)  ................................................................................... 26 
6.1.1  Dosage and Administration  ......................................................................................... 26 
6.2 Pi[INVESTIGATOR_399163]  ..................................................................................................................... 27 
6.2.1  Dosage and Administration  ......................................................................................... 28 
6.2.3  Dose Modification  ........................................................................................................ 29 
6.2.4  SRT and Dose Interruptions  ....................................................................................... 39 
6.2.5  Resumption of Treatment after Dose Delay  ..............................................................  40 
6.2.6  Concomitant and Excluded Therapi[INVESTIGATOR_014]  ....................................................................... 40 
6.2.7  Acceptable Concomitant Medications  ........................................................................ 40 
6.2.8  Permitted Therapi[INVESTIGATOR_014]: SRT  .......................................................................................... 41 
6.2.9  Permitted Therapy for Brain Edema  ......................................................................... 41 
6.2.10   Permitted Therapy: Brain Surgery  ........................................................................... 41 
7.0 Prohibited Concomitant Medications  ..................................................................................... 41 
Proprietary Information of MD Anderson
5 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
 Special Precautions  .............................................................................................................. 43 
8.0 Study Assessments  ...................................................................... Error! Bookmark not defined.  
8.1 Adverse Event (AE) Monitoring  ...................................... Error! Bookmark not defined.  
8.2 Informed Consent  ............................................................. Error! Bookmark not defined.  
8.3 Physical Examination  ....................................................... Error! Bookmark not defined.  
8.3.1  Full Physical Exam ............................................................ Error! Bookmark not defined.  
8.3.2  Directed Physical Exam  .................................................... Error! Bookmark not defined.  
Eastern Cooperative Oncology Group (ECOG) Performance Scale Error! Bookmark not defined.  
8.3.3  Vital Signs  .......................................................................... Error! Bookmark not defined.  
8.3.4  Response Assessment  ........................................................ Error! Bookmark not defined.  
8.4 Archival Tumor Tissue Sample  ....................................... Error! Bookmark not defined.  
8.5 Biopsy  ................................................................................. Error! Bookmark not defined.  
8.6 Laboratory Assessments  ................................................... Error! Bookmark not defined.  
8.7 Electrocardiogram  ............................................................ Error! Bookmark not defined.  
8.8 Neurological Function Testing  ......................................... Error! Bookmark not defined.  
ECOG Evaluation  ..................................................................... Error! Bookmark not defined.  
8.9 Research Sample Collection  ............................................. Error! Bookmark not defined.  
8.9.1  Tissue  .................................................................................. Error! Bookmark not defined.  
8.9.2  Blood  ................................................................................... Error! Bookmark not defined.  
Additional Local Testing  .......................................................... Error! Bookmark not defined.  
8.9.3  Cerebrospi[INVESTIGATOR_17106] (CSF)  ............................................... Error! Bookmark not defined.  
8.10  Tumor Imaging and Assessment of Disease  .................... Error! Bookmark not defined.  
8.11  Therapy Administration  ................................................... Error! Bookmark not defined.  
8.12  Management of Patients with disease progression  .............. Error! Bookmark not defined.  
8.13  Supportive Care Guidelines  ............................................. Error! Bookmark not defined.  
8.14  Patient Discontinuation  .................................................... Error! Bookmark not defined.  
8.15  Withdrawal  ........................................................................ Error! Bookmark not defined.  
8.16  End of Study  ...................................................................... Error! Bookmark not defined.  
8.[ADDRESS_503134] Study Drug Follow up  .............................................. Error! Bookmark not defined.  
8.[ADDRESS_503135] to Follow- up .............................................................. Error! Bookmark not defined.  
8.0 Schedule of Assessments  ...................................................................................................... 45 
9.0  Statistical Considerations  ....................................................................................................... 51 
9.1 Phase I  ........................................................................................................................... 64 
9.2 Phase II  ......................................................................................................................... 65 
Proprietary Information of MD Anderson
6 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503136] (IRB) Approval .......................................................................... 75 
Compliance with Trial Registration and Results Posting Requirements  ............................ 75 
11.3.4     Ethical Considerations  .............................................................................................. 76 
11.3.5  Informed Consent  ........................................................................................................ 76 
12.0  Study Documentation, Monitoring, and Administration  ........................................................ 76 
Appendices  ..................................................................................................................................... 77 
Cont
raception Requirements  .................................................................................................. 86 
Pregnancy Testing  .................................................................................................................. 88 
13.0  References  ............................................................................................................................. 95 
 
  
Proprietary Information of MD Anderson
7 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
 TRIAL  SUMMARY  
 
Title of Study Phase I/II Trial of Bintrafusp A lfa (M7824) and Pi[INVESTIGATOR_399164] [ADDRESS_503137] Phase Phase 1/2 
Numb er of Study  
Center(s)  
1 
Objectiv es Phase I Primary Objective  
 
• Establish safety profile and recommended phase II dose for combining Bintrafusp Alfa  
(M7824) and pi[INVESTIGATOR_399165].  
 
Phase II Primary Objective  
 
• Time to intracranial progression (defined as progression of existing lesions and development 
of new lesions  by [CONTACT_100694] 1.1) and Overall survival.  
 
Secondary Obje ctives 
• Intracranial progression 4, 8, 12, 16 weeks and every 8 weeks thereafter.  
• Intracranial objective response rate as measured by [CONTACT_95733] -BM, iRANO, and 
RECIST 1.1. 
• Time to second intracranial progression after Salvage SRS  
• Overall survival rate at 24, 52, 68 weeks.  
• Frequency of grade 3+ intracranial toxicities at 4 , 12, 24, 36, 52, and 68 weeks. . 
• Frequency of extracranial progression and response rate at 8, 16, 24, and every 8 
weeks thereafter.  
• Frequency of neurocognitive decline at 24, 52, and 68 weeks (optional).  
• Changes in neurocognitive function and health-related quality of life.  
• Dose, duration and frequency of steroid use for symptomatic management.  
Exploratory Obje ctives 
• Identify molecular and/or immunological markers from biospecimens (tissue, blood, and CSF ) that are associated with treatment response and toxicity.  
• Identify imaging biomarkers of response and toxicity (acute radiation effect/radionecrosis and neurocognitive changes) from multiparametric MRI and/or delayed PET that predict treatment response and toxicity.  
• Dose, duration and frequency of steroid use for symptomatic management.  
• To evaluate the potential correlation between mutational burden and tumor response  
Proprietary Information of MD Anderson
8 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
  
 
  
 
 
Study Design  
• Identify correlative or surrogative relationship between systemic (blood) 
and imaging markers and treatment outcomes.  
 
 
 
This study is an open -label Phase I/II trial to determine the safety and efficacy of pi[INVESTIGATOR_399166]  (M7824) in patients with brain metastases. The Phase I 
study will accrue patients with melanoma, lung, and breast cancers to a dose escalation phase 
as described below. The Phase II study will include expansion cohorts, of [ADDRESS_503138] also incorporated an early imaging time point to allow the application of stereotactic 
radiosurgery  (SRS) to intracranial lesions that are either progressing or not responding. This 
decision will be made in the context of multi -disciplinary care provided at the MD Anderson 
Brain Metastasis Clinic.  
 
Proprietary Information of MD Anderson
9 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
  
 
  
 Key Inclusion Criteria (Please see section 5.1 for complete eligibility criteria) 
 
1. Age ≥ 18 years old.  
2. Life Expectancy > [ADDRESS_503139] one measurable untreated brain lesion ≥ 0.5 cm and <3.[ADDRESS_503140] required or received systemic 
corticosteroid therapy in the 10 days prior to beginning protocol therapy. 
8. Prior treatment with immunotherapy and targeted therapy allowed as long 
as it did not include a combination of MEKi + anti- PD(L) -1 antibody and is 
>[ADDRESS_503141] received prior PD- 1 based therapy. 
11. Patients with TNBC and HR+ are included (any number of prior lines of therapy- including IO naïve patients).   
12. For HR+ patients, patients are allowed to receive endocrine therapy  
(Arimidex, letrozole, exemestane, or fulvestrant) . Concurrent CDK4/6 
inhibitors will not be allowed.  
13. Systematic radiation therapy is allowed (>14 day washout)  
14. Prior platinum -based chemotherapy for NSCLC patients is allowed   
 
 
Proprietary Information of MD Anderson
 Bintrafusp Alfa  (M7824)+Pi[INVESTIGATOR_399167], Version 5 
  
 9 
 
 
                                                                                       Exclusion Criteria  
 
1. Patients with clinical or radiographic evidence of leptomeningeal disease.  
2. Those who experienced grade 3 or 4 neurotoxicity from prior SRS.  
3. Contraindications to MRI (implanted metal device or foreign bodies) or MRI contrast (insufficient 
renal function or allergy).  
4. Subjects with major medical, neurologic or psychiatric condition who are judged as unable to fully comply with study therapy or assessments should not be enrolled.  
5. Active secondary malignancy unless the malignancy is not expected to interfere with the evaluation of 
safety and is approved by [CONTACT_978]. Examples of the latter include basal or squamous cell carcinoma of 
the skin, in -situ carcinoma of the cervix, and isolated elevation of prostate -specific antigen. Subjects 
with a completely treated prior malignancy and no evidence of disease for ≥ 2 year s are eligible.  
6. Has a known history of or is positive for hepatitis B (hepatitis B surface antigen [HBsAg] reactive) or 
known active hepatitis C virus infection (note treated and cured history of hepatitis C is 
allowed) (hepatitis C virus [HCV] RNA [qualitative] is detected). Note: Without known history, testing 
needs to be performed to determine eligibility. Hepatitis C antibody (Ab) testing is allowed for 
screening purposes in countries where HCV RNA is not part of stan dard of care.  
7. Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by [CONTACT_14306].  
8. The use of corticosteroids is not allowed for 10 days prior to initiation of therapy (based upon 5 times 
the expected half -life of dexamethasone) except patients who are taking steroids for physiological 
replacement. If alternative corticosteroid therapy h as been used, consultation with the PI  [INVESTIGATOR_399168].  
9. Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily 
prednisone equivalent) or other immunosuppressive medications within 14 days of study initiation. Inhaled or topi[INVESTIGATOR_8826], and adrenal replacement steroid  doses > 10 mg daily prednisone 
equivalent, are permitted in the absence of active autoimmune disease.  
10. Major surgical procedure, open biopsy (excluding skin cancer resection), or significant traumatic injury within 14 days of initiating study drug (unless the wound has healed) or anticipation of the need 
for major surgery during the study.  
11. Non-healing wound, ulcer . 
12. Women who are breast -feeding or pregnant.  
13. Subjects with a history of serious intercurrent chronic or acute illness, such as cardiac or pulmonary 
disease, hepatic disease, bleeding diathesis or recent major bleeding events or other illness considered by [CONTACT_399261]  
14. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months before start of study medication (except for adequately treated catheter -related venous thrombosis occurring more 
than 1 month before the start of study medication).  
15. History of clinically significant cardiac disease or congestive heart failure > [LOCATION_001] Heart Association (NYHA) class 2. Subjects must not have unstable angina (anginal symptoms at rest) or 
new-onset angina within the last [ADDRESS_503142] 6 months.  
16. Investigational drug use within 14 days (or 5 half -lives, whichever is longer) of the first dose of 
bintrafusp alfa and/or pi[INVESTIGATOR_399163].  
17. Has a history of (Grade 3 or 4) non -infectious pneumonitis that required steroids or current 
pneumonitis.  
18. Retinal degenerative disease (hereditary retinal degeneration or age -related macular degeneration), 
history of retinal vein occlusion (RVO) or any eye condition that would be considered as risk factor 
for RVO (e.g. uncontrolled glaucoma or ocular hypertens ion) 
20. Creatine phosphokinase level at baseline NCI CTCAE Grade ≥2 (>2.5x ULN – 5x ULN) and/or     
         previous history of myositis or rhabdomyolysis  
21. For NSCLC cohort patients whose tumor exhibit activating EGFR mutation, ALK         
          or ROS translocation and have a standard of care molecular targeted therapy     
          available for these mutations, will be excluded from this study. Patients who   
          
progressed or could not tolerate these standard of care molecular targeted agents  
         are eligible for this study. Lung adenocarcinoma patients may be consented prior  
          to the EGFR and ALK status being known, but EGFR and ALK status must be  
          determined prior to initiating therapy  
22.     Administration of live, attenuated vaccine therapi[INVESTIGATOR_399169] 4   
          weeks prior to day 1 of treatment and during therapy  
 
 
 
 
 
Proprietary Information of MD Anderson
10 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
1.0  BACKGROUND INFORMATION  
1.1 DISEASE BACKGROUND :  BRAIN METASTASES   
Metastatic tumors to the brain are by [CONTACT_399262], totaling about 170,000 per year and developi[INVESTIGATOR_399170] 40% of all advanced cancer patients. Patients with metastatic brain lesions far outnumber patients with primary brain tumors [1-3].  Patients with advanced malignancies have been surviving longer with improved control of extra- cerebral disease due to new 
targeted and immune therapi[INVESTIGATOR_014]. T hese therapeutic approaches (e.g., anti- PD-1 antibodies and BRAF-targeted therapy in melanoma, 
anti-HER2 in metastatic HER2+ breast cancer, epid ermal growth factor receptor (EGFR) tyrosine-kinase inhibitors in EGFR- mutated 
non-small cell lung cancer (NSLSC)) [1–3] increase efficacy allowing for improved survival. Indeed the 5-year outcomes from PD-1 
based therapy in melanoma indicate survivals rates of up to 40%, and in NSCLC, the 5- year OS in PD -L1 TPS 50 or above is 25%. 
[56] Hence, the incidence of brain metastases has been increasing.  Additionally, other factors may contribute, including improved detection of small metastases by [CONTACT_9252] (MRI).  Nonetheless, the incidence of BMs depends on the type of primary cancer, varying from approximately 5–50%. [4] CNS involvement occurs more commonly in lung cancer, breast cancer, 
melanoma, and renal cell carcinoma patients. [4] Metastatic CNS disease can have devastating neurologic effects including focal 
neurologic dysfunction, cognitive dysfunction, seizures, stroke-like symptoms, and death. The features that impact outcome of brain metastases include their primary histology, number, size and site of brain metastases, the status of extra -cranial disease, and the 
performance status of the patient . BMs are associated with a poor prognosis. Overall survival varies according to the tumor types and 
tumo r subtypes from 3 to 25 months.[4 ] 
 Novel therapeutic approaches are direly needed, and consideration needs to be made for combination of effective therapi[INVESTIGATOR_399171], immunotherapy, with radiation therapy. 
D
ISEASE BACKGROUND : RADIATION THERAPY FOR BRAIN METASTASES  
CNS directed therapi[INVESTIGATOR_184597], stereotactic radiosurgery (SRS) (gammaknife (GK), or whole brain radiation therapy (WBRT) 
have been the mainstay of therapy. However, the optimal treatment of multiple brain metastases is not well defined and still very 
inadequate. The paucity of data in the management of CNS metastases is further highlighted as patients with symptomatic brain  
metastases are often excluded from participation in clinical trials, thereby [CONTACT_399263]. Many 
Proprietary Information of MD Anderson
11 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503143] 65% probability of significant cognitive decline at 24 weeks associated with WBRT.[5] In addition, WBRT causes 
a minimum of 4 -6 weeks interruption of systemic therapy, which can lead to progression of systemic disease and worse survival.[6] As 
a result, there has been vigorous effort in recent years to improve treatment of brain metastasis. The outcomes of 86 melanoma pa tients 
with brain metastases were widely varied: in those treated with WBRT alone, the median survival was 3 months; in those treate d with 
SRS, the median survival was 7 months; and surgery was associated with a median survival of 11-12 months [27].  
Stereotactic radiosurgery (SRS) is a type of external radiation therapy that uses multiple beams to deliver a large dose of radiation to a 
tumor in a single session. SRS is conducted via a number of possible modalities including Gamma Knife or a conventional linear accelerator. Treatment is either as a single fraction or hypofractionated (within 3 -5 fractions). Generally speaking, SRS is utilized to 
treat a limited number of brain metastases while WBRT is utilized to treat more widespread disease. However, the definition of what constitutes limited versus widespread continues to evolve. SRS is highly preferred and can be utilized in 1- 3 metastases according to 
NCCN guidelines; however in practice, SRS is frequently utilized in patients with many more brain lesions [ 8]. The use of 
immunotherapy may complement radiation therapy because the latter damages the blood brain barrier (BBB), alters the tumor microenvironment, and increases immunogenicity of tumors. 
Two phase III trials in p atients with 1 -3 brain metastases, one conducted at MD Anderson [9] and one through a cooperative group,[10] 
have established SRS as the standard care in this patient population.  Currently we are investigating whether the use of SRS can be 
expanded to patients with more brain metastases in a phase III trial randomizing patients with 4- 15 brain metastases to SRS vs. WBRT 
([STUDY_ID_REMOVED]).  
There is pre- clinical and clinical data suggesting clinical activity of systemic anti- neoplastic therapi[INVESTIGATOR_014], including immunotherapi[INVESTIGATOR_399172]. One of the challenges of treating brain metastases is the blood -brain barrier leading to poor perm eability of many 
drugs. The blood- brain barrier is a highly selective permeability barrier comprised of capi[INVESTIGATOR_117749], which are connected 
by [CONTACT_399264] S compartment [ 11, 12]. 
Proprietary Information of MD Anderson
12 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503144] 
from the primary site or extracranial metastatic sites and may be more resistant to cytotoxic and targeted therapi[INVESTIGATOR_014] [ 13, 14]. 
 
1.2  DISEASE BACKGROUND :  BRAIN METASTASES AND MELANOMA  
 
Cutaneous malignant melanoma is the most aggressive form of skin cancer, accounting for the large majority of skin cancer -related 
deaths.  The global incidence continues to rise, with current estimates of 132,000 new diagnoses/year and 37,000 deaths [29]. Melanoma 
accounts for ~5% of all new cases of cancer in the [LOCATION_002] (US). The incidence of melanoma continues to rise by [CONTACT_34120] 3% per 
year in the US. In 2016, there will be an estimated 76,380 new melanoma patients and 10,130 melanoma -related deaths  in the [LOCATION_003]. [29] 
Melanoma is one of the few tumors whose incidence is still increasing, despi[INVESTIGATOR_399173]. The 
majority of patients present with localized disease and their prognosis is excellent if primary tumors are 1.0 mm or less in thickness. 
However, when there is lymph node involvement, survival rates are roughly halved due to the significant increase in the risk of distant 
systemic metastases including to lung, liver, and brain. Patients with metastatic disease historically face long -term survival rates of less 
than 10%, although this scenario is dramatically changing after the emergence of groundbreaking systemic therapi[INVESTIGATOR_014], including BRAF 
and MEK inhibitors for patients harboring a BRAF mutation, immunotherapeutic agents such as Cytotoxic T -Lymphocyte Antigen 4 
(CTLA4) inhibitors and especially Programmed Death 1 (PD -1) inhibitors.[5-11] Long- term remissions are being increasingly observed 
in patients that respond to therapy, bringing new hope and excitement to the field.  Population studies demonstrate cutaneous melanoma is the third most common cause of brain metastasis development only after t he 
lung and breast cancer, reflecting its distinctive neurotropi[INVESTIGATOR_8801].[30 -32] Approximately 40- 50 % of stage IV melanoma patients eventually 
develops clinical manifestations of melanoma brain metastasis (MBM). [33] The prevalence is likely higher as autopsy series have 
reported 55–75 % of melanoma patients have MBM.[34, 35]  Although outcomes differ for patients with MBM, overall prognosis 
remains poor. The overall survival reflects the effects of therapy on both intracranial and extracranial disease at the time of presentation and may not be entirely representative of intracranial disease control. Even with early diagnosis and aggressive local therapy, MBM is the cause of death in nearly 95 % of patients.[31] The bleak outcomes of MBM have not been mitigated over the past three decades, and 
although the last [ADDRESS_503145] majority of clinical trials of 
investigating systemic therapy.   
Proprietary Information of MD Anderson
13 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 The management of MBM has been traditionally limited to surgical or radiotherapy approaches. However, melanoma is a relatively 
radiation -resistant tumor; as melanoma cells were shown in early in vitro studies to have a low responsiveness to radiation, which 
corresponded with documented low efficacies of WBRT in clini cal use. [36]   Patients with MBMs who underwent WBRT treatment 
alone even in the early 2000’s had a median survival of only 3.4 months compared with 2.1 months if they received supportive care 
alone. [37-40] Given this limited benefit, WBRT use is generally limited to MBM patients with no surgical options, symptomatic diffuse 
disease, large volume single lesions or leptomeningeal spread of disease. In contrast to the limited role of WBRT, SRS has emerged as 
a highly effective local therapeutic approach to MBM treatment.  Since the studies performed by [CONTACT_399265]. [30, 31]  in the 1990’s, 
the overall management of brain metastases has changed significantly.   The added value of WBRT to SRS is questionable; a ran domized 
trial involving multiple tumor types showed that intracranial metastatic control following WBRT+SRS was not significantly different 
than after SRS alone, and OS was also equivalent. [41] Additionally, the response of brain metastases was independent of cancer type 
and previously designated radio- resistance. [42] Further, a small study comparing WBRT alone to WBRT+SRS was stopped early due 
to a 1 -year local failure rate of 100% in those undergoing WBRT alone versus only an 89% failure rate in those undergoing 
WBRT+SRS. [43] SRS alone has therefore now become the standard treatment for the majority of patients with limited MBMs.    
 Systemic therapy has not been used effectively. Discovery of driver mutations in RAS -MAP -kinase signaling pathway has led to the 
development of agents targeting specific enzymes including BRAF and MEK. Single -agent BRAF inhibitors dabrafenib and 
vemurafeni b have been proven safe to administer in patients with BRAF -mutated melanoma and active MBM and have activity that 
parallels extracranial activity with objective intracranial response rate (OIRR) of 35 -42%. [45, 46]  Still, progression- free and overall 
survi vals are still lower for this population than for patients with only extracranial metastases, with few systemic alternatives for patients 
after progression. Furthermore, BRAF mutation is only detected in about half of melanoma patient. The combination of BRAF inhibitor dabrafenib and MEK inhibitor trametinib is being evaluated for active melanoma brain metastasis in a clinical trial (Study Registry ID: [REMOVED]).   The recent approval of immunotherapeutic agents has also brought some enthusiasm for this population. Single -agent ipi[INVESTIGATOR_399174] (vs) extracranially, but still with low response rates (up t o 16%), and 
mostly in asymptomatic patients. [20] Pembrolizumab was studied in 18 patients with untreated or progressive MBM, with 4 durable 
responses (22%), including 2 complete responses.[21] This promising activity from immunotherapy in brain metastasis, however, is 
restricted by [CONTACT_399266], as was the case with ipi[INVESTIGATOR_125], which can pose a problem since corticosteroids can be crucial to managing perilesional edema in the brain. In addition, immunotherapy with PD -
1 antibodies itself can induce further swelling by [CONTACT_399267]. In the study with pembrolizumab, 17% of 
treated patients experienced seizure activity, indicating a potential need for strategies to reduce or l imit perilesional edema that do not 
curtail the immunotherapeutic effect.  
Proprietary Information of MD Anderson
14 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503146] led to intracranial responses with systemic therapy. Targeted therapy with BRAF/MEKi leads to a high rate of intracranial responses similar to extracranial disease albeit of seemingly shorter d uration. 
Immunotherapy with combination anti -CTLA4 and anti -PD-[ADDRESS_503147] the following characteristics: a) clinical responses as early as 6 weeks, b) complete responses in 26% and overall objective response rate in 56% of patients, c) durability in >90% of patients, d) high concordance between extracranial and i ntracranial 
disease, and e) high progression free survival rates of >60% at one year. [53, 54].  
1.3
  DISEASE BACKGROUND :  BRAIN METASTASES AND BREAST CANCER  
 
Brain metastases (BMs) are the most common central nervous system (CNS) tumors in adults. The incidence of BMs is increasing due to both improved diagnostic techniques (e.g. magnetic resonance imaging: (MRI) and increased cancer patient survival through advanced systemic treatment approaches (e.g. anti -HER2  in metastatic HER2  breast cancer, epi[INVESTIGATOR_3506] (EGFR) tyrosine -
kinase inhibi tors in EGFR -mutated non- small cell lung cancer (NSCLC) [23 -25]. The incidence of BMs depends on the type o f primary 
cancer, varying from approximately 5–50% [4].  CNS involvement occur more commonly in lung cancer, breast cancer, melanoma, and 
renal cell carcinoma patients[4].  BMs are associated with a poor prognosis. Overall survival varies according to the tumor types and 
tumor subtypes from 3 to 25 months[4].  In breast cancer, differences in survival of patients with BMs by [CONTACT_399268] (luminal, H ER2 
and triple -negative metastatic breast cancer) have been observed and highlight the need for a tailored approach in this patient 
population[5]. Several predicting factors for BMs have been identified to date and include age, histological grade, negative status of 
estrogen receptor, HER2  and number of non- CNS metastatic sites (1 versus  >1) [26]. 
  
To date, general indications to use systemic treatments for BMs is limited to highly chemotherapy -sensitive primary tumors, BMs 
from primary tumors with identified molecular alterations a menable to targeted therapy crossing the BBB, asymptomatic BMs found 
on screening MRI with planned systemic treatment, or in cases in which other therapeutic options have been exhauste d and there is a 
drug available [7]. This is due to the lack of efficacy of systemic treatment including in breast cancer patients with BMs. 
Consequently, until recently, treatment of BMs from breast cancer was focused on local therapy (surgery or radiotherapy) [27].  
Indeed, adding active systemic therapy to local (radiation, surgery) therapy could be one effective way to improve the outcom e of 
patients with BMs. The concept aims to use and to enhance both local and systemic effects of the treatment. The immune stimulatory effects of radiation therapy in combination with immunotherapy [e.g. checkpoint inhibitors, CAR (chi meric antigen receptor) -T cell
 
[28] is an example of this innovative approach. 
Proprietary Information of MD Anderson
15 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503148] cancer, differences in survival of patients with BMs by [CONTACT_399268] (luminal, HER2 and triple -negative metastatic breast 
cancer) have been observed and highlight the need for a tailored approach in this patient population.[5] Several predicting factors for 
BMs have been identified to date and include age, histological grade, negative status of estrogen receptor, HER2 and number of non-
CNS metastatic sites (1 versus >1). [6]  
 
1.4 DISEASE BACKGROUND :  BRAIN METASTASES AND LUNG CANCER  
Lung cancer is the leading cause of worldwide cancer mortality, and is responsible for more deaths annually in the [LOCATION_002] than 
the combination of breast, colorectal, and prostate cancer, with an estimated 1.04 million new cases each year worldwide [15,16] .   Non–
small cell lung cancer (NSCLC) accounts for approximately 75% of all lung cancers. Of these, approximately one third will develop brain metastasis at some time during the course of their disease . Brain metastases are a common problem in patients with metastatic 
NSCLC . About 7% –10% of NSCLC  patients present with brain metastases at the time of initial diagnosis, and as many as 20% –40% of 
patients develop brain metastases at some point during their illness[17-20]. Additionally, 50% of all brain metastases are from lung 
primary tumors [21].  Unfortunately for the vast majority of these patients, this diagnosis is associated with significant morbidity in 
addition to shortened survival.  Present treatments for brain metastases include surgery in select patients with limited intr acranial and 
systemic disease burden and good performance status. However, the majority of patients receive treatment for their brain metastases  via 
whole brain radiation Therapy (WBRT) and Stereotactic Radiosurgery (SRS).  These modalities are often quite effective in alleviating symptoms; however, median survival remains poor, estimated to be between 2-7 months [22]. Clearly new treatments are needed.  
 Radiation is commonly utilized to treat brain metastases via WBRT or SRS. Generally speaking, SRS is utilized to treat a limited number of brain metastases while WBRT is utilized to treat more widespread disease. However, the definition of what constitutes  limited versus 
widespread continues to evolve. WBRT can be conducted utilizing a number of different treatment machines and is most typi[INVESTIGATOR_1306] y 
performed with a conventional linear accelerated. WBRT is given through a fractionated schedule with a typi[INVESTIGATOR_399175] 30 Gy in 10 fractions. On the other hand SRS is conducted via a number of possible modalities including Gamma Knife or a conventional linear accelerator. Treatment is either as a single fraction or hypofractionated (within 3- 5 fractions).  
  
Therapeutic Agents Background:  BINTRAFUSP ALFA (M7824)  and Pi[INVESTIGATOR_399176]’ s Brochure (IB)/approved labe ling for detailed background informa tion on Bintrafusp Alfa  (M7824) and 
Pi[INVESTIGATOR_399163].   
Proprietary Information of MD Anderson
16 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Background on Bintrafusp Alfa  (M7824)  
Bintrafusp Alfa  (M7824) is a novel fusion protein comprised of the extracellular domain of the human TGFβ -RII (transforming growth 
factor beta –receptor II) that is covalently linked to the C -terminus of the heavy chain of the anti -PD-L1 (anti -programmed death ligand 
1) antibody via a flexible (Gly 4Ser) 4G linker. The anti -PD-L1 moiety of Bintrafusp Alfa  (M7824) is identical to anti- PD-L1 
monoclonal antibody avelumab, except for 3 amino acid substitutions in the heavy chain constant regions that result in a diff erent 
human IgG1 allotype, and one amino acid substitution in the heavy chain for antibody fusion protein stability. As of June 2017, FDA 
has granted accelerated approval to avelumab for metastatic Merkel cell carcinoma (MCC) and locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy. 
The TGFβRII component functions as a TGFβ neutralizing ‘trap”.  Bintrafusp Alfa (M7824) is designed to target two negative regulatory 
pathways in immunosuppression: the cell -intrinsic one mediated by [CONTACT_399269] -immune cell interaction, in which programmed death 
ligand- 1 (PD -L1)/programmed  
1.5  PI[INVESTIGATOR_399177] -mole cule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic 
activity.  Pi[INVESTIGATOR_399178]1/2, preventing the activation of MEK1/2- dependent 
effector proteins and transcription factors, which may result in the inhibition of growth factor -mediated cell signaling and tumor 
cell proliferation. M EK1/2 (MAP2K1/K2) are dual -specificity  threonine /tyrosine  kinases that play key roles in the activation of 
the RAS/RAF/ MEK /ERK pathway and are often upregulated in a variety of tumor cell types.  
Pi[INVESTIGATOR_399163]  (MSC1936369B) is an orally bioavailable and selective small-molecule inhibitor of MEK1 and MEK2 that prevents the 
activation of MEK1/2-dependent effector proteins and transcription factors [47, 48]. It has demonstrated robust antitumor activity in 
preclinical studies, including tumor growth reduction in murine myeloma xenografts [47] and tumor regression in a mouse model of 
D-MUT colorectal cancer [48] and it has also been shown to circumvent resistance to BRAF inhibition in human melanoma cells [47]. 
Pi[INVESTIGATOR_399179] a single agent showed acceptable toxicity with a maximum tolerated dose (MTD) that depended on the treatm ent  
schedule in patients with advanced solid tumors [49];  with continuous twice daily administration, the MTD was 75 mg. When 
pi[INVESTIGATOR_399180] (5-fluorouracil/folinic acid/irinotecan), the MTD was reached at 45 mg/day in a 5 
days on/2 days off schedule in patients with KRAS -mutated metastatic colorectal cancer [50]. 
Proprietary Information of MD Anderson
17 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 2.0  RATIONALE  FOR THE STUDY  
 
2.1   R ATIONALE FOR COMBINING IMMUNOTHERAPY WITH TARGETED THER APY IN THE TREATMENT OF BRAIN METASTASES  
 
Immunotherapi[INVESTIGATOR_399181] (APCs), T lymphocytes, and cancer cells to potentiate an anti -tumor immune response have been developed, with many recently approved by [CONTACT_399270]. Over the past few years, immunomodulation has come to be a mainstay in the treatment algorithm in many malignancies, including melanoma and NSCLC, and a number of other cancers . 
Nonclinical data show a negative association between MEK activity and active antigen presentation (MHC -1 and II expression) 
that appears to be coupled to simultaneous PD -L 1 expression [51- 52]). These findings link the MAPK pathway activation to 
the tumor immun e-evasion. Consistently, MEK inhibition results in an increased number of tumor -infiltrating CDS -positive T 
lymphocytes and PD -L 1 and MHC expression [51-52]. These effects are responsible for the enhanced anti -tumor immune 
response observed with the combination of MEK with PD -L 1/PD -1 inhibitors [52] . 
 The combination of a MEKi with immunotherapy has been studied in preclinical models and confirmed the presence of additivity if not synergy. The combination of cobimetinib and atezolizumab has also shown up to 50% ORR in patients with melanoma in a Phase I  study and has now moved into the Phase III setting. IMspi[INVESTIGATOR_399182] a Phase III study currently examining the 
combination of cobimetinib+atezolizumab vs pembrolizumab in patients with BRAF -wt melanoma ([STUDY_ID_REMOVED]).  
 While there are number of trials looking into every possible combination of t argeted therapi[INVESTIGATOR_399183], there is no clinical trial 
specifically in NSCLC has been matured yet.  [57]  
Standard Treatment for patients with oligo -brain metastases remains ster eotactic radiosurgery. In recent years, immunotherapy 
and MEK inhibitors have shown intracranial activity in melanoma patients with brain metastases, raising question on whether such intracranial activity from immunotherapy and target agents can have sufficient intracranial activity to hold or delay SR S 
with the goal to minimize SRS treatment toxicity, without compromising patients’ surviv al or intracranial control.  
 
Pi[INVESTIGATOR_399184]. Finally, using a bispeci fic 
PD-L1 and TGFβ neutralizing ‘trap” tackles [ADDRESS_503149], and lung cancers. 
Proprietary Information of MD Anderson
18 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 The goal of this combination is ultimately to seek synergy between MEK inhibition and the dual inhibition of PD-1/PD-L1 pathway 
and TGFbeta. It is also conceivable that potentiating the immune response, while augmenting tumor response, could also result in  a 
higher rate of toxicities. At one level, immune -related toxicities could be augmented with specific attention being paid to pneumonitis 
and liver dysfunction. While the mechanism by [CONTACT_399271], it could still be perpetuated in the presence of an immune response. We will follow patiens closely for those events and manage promptly. Another potential overlappi[INVESTIGATOR_399185]. However, MEKi have been combined safely with anti- PD-L1 previously as in the Phase III study of 
cobimetinib+atezolizumab +/- regorafenib in colorectal cancer  [58].  
 
2.2  Rationale for combining immunotherapy with stereotactic radiosurgery (SRS) in the treatment of brain metastases  
There is pre- clin ical and clinical data suggesting clinical activity of systemic anti- neoplastic therapi[INVESTIGATOR_014], including immunotherapi[INVESTIGATOR_399172]. One of the challenges of treating brain metastases is the blood -brain barrier leading to poor perm eability of many 
drugs. The blood- brain barrier is a highly selective permeability barrier comprised of capi[INVESTIGATOR_117749], which are connected 
by [CONTACT_399264] S compartment [ 48, 49]. 
Additionally, as brain metastases tend to occur later in the disease course, these tumors may be biologically and genomically distinct from the primary site or extracranial metastatic sites and may be more resistant to cytotoxic and targeted therapi[INVESTIGATOR_014] [ 50]. 
Radiation, in addition to providing effective local treatment through its tumoricidal effect via generation of DNA double strand breaks, has been found in recent years to trigger an immune response, leading to improved local control and abscopal effect (tumor regression 
in non- irradiated sites).  This is achieved through radiation induced tumor neoantigen release, MHC class I expression, and pro-
inflammatory cytokine release. Additionally, radiation has been found to modulate the immune suppressive tumor mi croenvironment 
by [CONTACT_399272]. The best radiat ion 
regimen in inducing or supporting immune response is yet to be identified. Although stereotactic radiosurgery (SRS), which delivers high dose radiation in a single fraction was thought to generate the most robust immune response,  recent pre -clinical study demonstrated 
that fractionated stereotactic radiation therapy (FSBRT), where radiation is delivered in 3- [ADDRESS_503150] with other CNS -penetrant small molecules to modulate 
tumor microenvironment and to enhance tumor killing. 
3.0
  S TUDY DESIGN  
 
Proprietary Information of MD Anderson
19 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 This study is an open- label Phase I/II trial to determine the safety and efficacy of pi[INVESTIGATOR_399186] 
(M7824) in patients with brain metastases. The Phase I study will accrue patients with melanoma, lung, and breast cancers to a dose 
escalation phase as described below. The Phase II study will include expansion cohorts, of [ADDRESS_503151] also incorporated an early imaging time point to allow the application of SRS to intracranial lesions that are either  
progressing or not responding. This decision will be made in the context of multi-disciplinary care provided at the MD Anderson Brain Metastasis Clinic.  
 Phase I:  
The phase I dose finding part of the study is to determine the recommended phase II dose (RP2D) of Bintrafusp Alfa  (M7824) + 
pi[INVESTIGATOR_399187]. The planned DL1 and DL2 doses are Bintrafusp Alfa  (M7824) flat dose of 1200 mg 
every 2 weeks and pi[INVESTIGATOR_399163] 45 mg PO BID (Dose Limit or DL1) and 60 mg PO BID (DL2), and fallback doses DL- 1 are Bintrafusp 
Alfa (M7824) flat dose of 1200 mg every 2 weeks and Pi[INVESTIGATOR_399188] 30 mg PO BID. Every cycle will be 28 days. We will enroll up to 
12 patients to the Phase I portion (18, should the trial de- escalate to DL -1). The standard “3+3” design will be employed to determine 
the RP2D. If DL1 is considered too toxic, DL-1 will be explored; if unacceptable toxicity is observed at DL -1, alternative dose 
schedules may be evaluated in an amendment.  The recommended phase II dose (RP2D) is defined as the highest dose level with no more than 1 patient with DLT out of 6 patients that are treated.   Please note that the study plans on enrolling up to 2 cohorts in Phase 1 
of the trial (the 45mg and either the 30 or 60 mg, depending on the safety of Cohort 1).    Phase II:  
The purpose of phase II part is to estimate the time to intra -cranial progression and overall survival time.  In this part, we will enroll 
up to [ADDRESS_503152] data for future larger studies.  Specifically, we would like to estimate time to intracranial progression considering death as a competing risk and overall survival time using Kaplan-Meier method, both with 95% confidence interval. 
 
   
Proprietary Information of MD Anderson
20 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Figure 1:  Study Schema 
 
 
  
 
DL-1 30 BID Pi[INVESTIGATOR_399189]1 45 BID Pi[INVESTIGATOR_399189]2 60 BID Pi[INVESTIGATOR_399163]  
  [Study Schema] – S ee Schedule of Assessments   
4.0
  OBJECTIVES  
 
 4.1 P RIMARY OBJECTIVE  
 4.1.1 P HASE I PRIMARY OBJECTIVE  
 Establish safety profile and recommended phase II dose for combining pi[INVESTIGATOR_399190] b intrafusp alfa (M7824) 
in patients with brain metastases.  
 4.1.2 P HASE II PRIMARY OBJECTIVE  
Cycle 1  
RP2D 
Cycle 2  
Cycle 3  
Pi[INVESTIGATOR_399191] 28 days (continuous dosing)  
BINTRAFUSP ALFA (M7824) 1200 mg (every 2 weeks)  
Cycle [ADDRESS_503153]  
 
Proprietary Information of MD Anderson
21 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 •  Time to intracranial progression (defined as progression of existing  lesions and development of new 
lesions by [CONTACT_100694] 1.1)  
•       Overall survival. 
 4.2 S ECONDARY OBJECTIVES  
• Intracranial progression 4, 8, 12, 16 weeks and every 8 weeks thereafter.  
• Intracranial objective response rate as measured by [CONTACT_95733] -BM, iRANO, and RECIST  1.1. 
• Time to second intracranial progression after Salvage SRS  
• Overall survival rate at 24, 52 and 68 weeks . 
• Frequency of grade 3+ intracranial toxicities at 4, 12, 24, 36, 52, and 68 weeks.Frequency of extracranial 
progression and response rate at 8, 16, 24, every 8 weeks . 
• Frequency of neurocognitive decline 12, 24, 36 weeks (optional).Changes in neurocognitive function and health-related quality of life.  
• Dose, duration and frequency of steroid use for symptomatic management. 
• Evaluation of safety and tolerability of pi[INVESTIGATOR_399163]/bintrafusp alfa combination  
 4.3 E
XPLORATORY OBJECTIVE  
• Identify molecular and/or immunological markers from biospecimens (tissue, blood, and CSF ) that are associated 
with treatment response and toxicity. 
• Identify imaging biomarkers of response and toxicity (acute radiation effect/radionecrosis and neurocognitive changes) from multiparametric MRI and/or delayed PET that predict treatment response and toxicity.  
• Identify correlative or surrogative relationship between systemic (blood) and imaging markers and treatment outcomes. 
 
5.0 P
ATIENTS  
Proprietary Information of MD Anderson
22 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 5.1 I NCLUSION CRITERIA  
1.       Age ≥ 18 years old. 
2. Life Expectancy > [ADDRESS_503154] one measurable untreated brain lesion ≥ 0.5 cm and <3.[ADDRESS_503155] required or 
received systemic corticosteroid therapy in the 10  days prior to beginning protocol therapy. 
8. Prior treatment with immunotherapy and targeted therapy allowed as long as it did not include a combination of MEKi + anti-PD(L)-1 antibody and is >[ADDRESS_503156] received prior PD -1 based therapy. 
11. Patients with TNBC and HR+ are included (any number of prior lines of therapy- including IO naïve patients).   
12. For HR+ patients, patients are allowed to receive endocrine therapy ( anastrozol e, letrozole, exemestane, or fulvestrant ). 
Concurrent CDK4/6 inhibitors will not be allowed.  
13. Systematic radiation therapy is allowed (>14 day washout)  
14. Prior platinum-based chemotherapy for NSCLC patients is allowed  
15. Adequate organ function as described below: 
 
System  Laboratory Value  
Hematological  
Absolute neutrophil count (ANC)  ≥1500/µL  
Platelets  ≥100  000/µL  
Proprietary Information of MD Anderson
23 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Hemoglobin  ≥9.0 g/dL or ≥5.6 mmol/La 
Renal  
Creatinine OR 
Measured or calculated b creatinine clearance  
(GFR can also be used in place of creatinine 
or CrCl)  ≤1.5 × ULN OR 
≥60 mL/min for participant with 
creatinine levels >1.5 ×  institutional ULN  
Hepatic  
Total bilirubin  ≤1.5 ×ULN OR direct bilirubin ≤ULN for 
participants with total bilirubin levels 
>1.5 × ULN  
AST (SGOT) and ALT (SGPT)  ≤2.5 × ULN (≤5  × ULN for participants 
with liver metastases)  
Coagulation  
International normalized ratio (INR) OR 
prothrombin time (PT) 
Activated partial thromboplastin time (aPTT)  ≤1.5 × ULN unless participant is 
receiving anticoagulant therapy as long as 
PT or aPTT is within therapeutic range of 
intended use of anticoagulants  
ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); 
AST  (SGOT)=aspartate aminotrans ferase (serum glutamic oxaloacetic transaminase); 
GFR=glomerular filtration rate; ULN=upper limit of normal.  
a Criteria must be met without erythropoietin dependency and without packed red blood 
cell (pRBC) transfusion within last 2 weeks.  
b Creatinine clearance (CrCl) should be calculated per institutional standard.  
Note: This table includes eligibility -defining laboratory value requirements for treatment; 
laboratory value requirements should be adapted according to local regulations and 
guidelines for the administration of specific chemotherapi[INVESTIGATOR_014].  
 
Proprietary Information of MD Anderson
24 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Women of child- bearing potential  (WOCBP)  must not be breastfeeding and must have a negative pregnancy test within [ADDRESS_503157] agree to adhere t o the contraceptive guidance in Appendix 5.  
 
Note:  A female participant is eligible to participate if she is not a woman of child bearing potential as defined in Appendix 5. 
 Fertile men must agree to use an acceptable method of birth control as described  in Appendix [ADDRESS_503158] be  resolved (to ≤ Grade 1 or Baseline) prior to study treatment administration, unless stable status as assessed by [CONTACT_1697] e.g. hypothyroidism, adrenal insufficiency, or other.Steroids for physiological replacement are allowed. 
5.2 E
XCLUSION CRITERIA  
1.       Patients with clinical or radiographic evidence of leptomeningeal disease. 
2.       Those who experienced grade 3 or 4 neurotoxicity from prior SRS. 
3. Contraindications to MRI (implanted metal device or foreign bodies) or MRI contrast (insufficient renal function or allergy). 
4. Subjects with major medical, neurologic or psychiatric condition who are judged as unable to fully comply with study therapy 
or assessments should not be enrolled. 
5. Active secondary malignancy unless the malignancy is not expected to interfere with the evaluation of safety and is approved by [CONTACT_978]. Examples of the l atter include basal or squamous cell carcinoma of the skin, in -situ carcinoma of the cervix, and isolated 
elevation of prostate -specific antigen. Subjects with a completely treated prior malignancy and no evidence of disease for ≥ 2 
years are eligible.  
6. Has a known history of or is positive for hepatitis B (hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus infection (note treated and cured history of hepatitis C is allowed) (hepatitis C virus [HCV] RNA [qualitative] is detected). 
Note: Without known history, testing needs to be performed to determine eligibility. Hepatitis C antibody (Ab) testing is all owed 
for screening purposes. 
7. Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by [CONTACT_14306]. 
8. The use of corticosteroids is not allowed for 10 days prior to initiation of therapy (based  upon 5 times the expected half -life of 
dexamethasone) except patients who are taking steroids for  physiological replacement. If alternative corticosteroid therapy has 
been used, consultation with the PI  [INVESTIGATOR_399192]. 
Proprietary Information of MD Anderson
25 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 9. Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other 
immunosuppressive medications within 14 days of study initiation. Inhaled or topi[INVESTIGATOR_8826], and adrenal replacement steroi d 
doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease. 
10. Major surgical procedure, open biopsy (excluding skin cancer resection), or significant traumatic injury within 14 days of initiating study drug (unless the wound has healed) or anticipation of the need for major surgery during the study. 
11. Non-healing wound, ulcer, or bone fracture. 
12. Women who are breast -feeding or pregnant. 
13. Subjects with a history of serious intercurrent chronic or acute illness, such as cardiac or pulmonary disease, hepatic d
isease,  bleeding diathesis or recent major bleeding events  or other illness considered by [CONTACT_399273] 
14. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep ve 
in thrombosis or pulmonary embolism within the 6 months before start of study medication (except for adequately treated 
catheter -related venous thrombosis occurring more than 1 month before the start of study medication). 
15. History of clinically significant cardiac disease or congestive heart failure > [LOCATION_001] Heart Association (NYHA) class 2. Subjects must not have unstable angina (anginal symptoms at rest) or new -onset angina within the last [ADDRESS_503159] 6 months. 
16. Investigational drug use within 14 days (or 5 half -lives, whichever is longer) of the first dose of bintrafusp alfa  and/or pi[INVESTIGATOR_399163] . 
17. Has a history of (Grade 3 or 4) n on-infectious pneumonitis that required steroids or current pneumonitis. 
18. Retinal degenerative disease (hereditary retinal degeneration or age -related macular degeneration), history of retinal vein 
occlusion (RVO) or any eye condition that would be considered as risk factor for RVO (e.g. uncontrolled glaucoma or ocular hypertension) 
19. Creatine phosphokinase level at baseline NCI CTCAE Grade ≥2 (>2.5x ULN – 5x ULN) and/or previous history of myositis or 
rhabdomyolysis 
20. For NSCLC cohort patients whose tumor exhibit activating EGFR mutation, ALK         
      or ROS translocation and have a standard of care molecular targeted therapy     
available for these mutations, will be excluded from this study. Patients who   progressed or could not tolerate these standard of care molecular targeted agents  are eligible for this study. Lung adenocarcinoma patients may be consented prior  to the EGFR and ALK status being known, but EGFR and ALK status must be  determined prior to initiating therapy   
22.
         Administration of live, attenuated vaccine therapi[INVESTIGATOR_399193] 4 weeks prior to day 1 of treatment and during therapy.  Locally      
Proprietary Information of MD Anderson
26 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
            approved COVID- 19 vaccines are allowed.  
6.0 T RIAL  TREATMENT  
 6.1 BINTRAFUSP  ALFA  (M7824)   
Bintrafusp alfa (M BINTRAFUSP ALFA (M7824)  drug product is a sterile, liquid formulation  formulation presented at a 
concentration of 600 mg/vial in [LOCATION_002] Pharmacopeia (USP) type I glass vial closed with a rubber stopper and sealed 
with an aluminum plastic crimpi[INVESTIGATOR_397263].  
Each vial contains 600 mg of Bintrafusp alfa ( BINTRAFUSP ALFA (M7824)  BINTRAFUSP ALFA (M7824)  as a preservative-
free histidine -buffered solution (pH=5.5) containing trehalose dihydrate, sodium chloride, L -methionine and polysorbate 20 
(Tween 20). Only excipi[INVESTIGATOR_399194] (M7824)  drug product. 
Subjects will receive IV infusion of Bintrafusp alfa ( BINTRAFUSP ALFA (M7824)  BINTRAFUSP ALFA (M7824)  over 1 
hour ( -10 minutes / +20 minutes) once every 2 weeks as detailed in the Schedules of Assessments. Modifications of the infusion 
rate due to infusion- related reactions are described in Section 6.2.3.  
Bintrafusp Alfa  (M7824) will be shipped in transport cool containers (2°C to         8°C) that are monitored with temperature 
control devices. 
 All IMPs will be packaged and labeled in accordance with  all applicable  regulatory requirements and Good Manufacturing 
Practice Guidelines.  
 
 6.1.1 D OSAGE AND ADMINISTRATION  
The dose for Bintrafusp Alfa  (M7824) is a flat dose of 1200mg. Subjects will receive Bintrafusp Alfa  (M7824) once every [ADDRESS_503160] may benefit from treatment beyond 
Proprietary Information of MD Anderson
27 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 12 months, it may be permissible after discussion with the EMD Ser ono.  If there is no evidence of radiographic or clinical 
progression, then the patient may continue on study at the discretion of the principal investigator. 
Participants who are discontinued due to an AE that are subsequently well managed or resolved after stoppi[INVESTIGATOR_7374], but pri or 
to the end of the study. Prior to reinitiation, the Principal Investigator [INVESTIGATOR_399195], such as that which led to initial treatment discontinuation. For participants with onl y 
stable disease at the time of discontinuation, the Principal Investigator [INVESTIGATOR_399196].  
In addition, to be eligible for reinitiation  (after dose delay) , the participant must not have previously withdrawn consent for this 
trial and should have been followed up with regular eCRF documented evaluation scans up to reinitiation of treatment. Prior to reinitiation of the study intervention, malignant  disease must be radiologically restaged within [ADDRESS_503161] be available and verified. The Principal Investigator [INVESTIGATOR_399197] a c ase-by- case basis. A discussion with the study team is warranted to determine whether 
PK/b iomarker testing is indicated upon restarting treatment.  
The participant should reinitiate treatment at the treatment phase visit where they left off according to the Schedule of 
Activities. Participants who reinitiate treatment should stay on study and should be treated and monitored according the Schedule of Activities for the rest of the study.   
 6.2 P
IMASERTIB  
 The drug substance pi[INVESTIGATOR_399163] (recommended international non-    proprietary name [INN]; also known 
as MSC1936369B or AS703026) is a   biaryl amine derivative. Its chemical name [CONTACT_399291] (IUPAC) is N- [(2S)-2,3-    dihydroxypropyl]-3- [(2-
fluoro 4-iodophenyl) amino] isonicotinamide    hydrochloride. 
 Pi[INVESTIGATOR_399198] 15mg and 30mg (as free base) hard gelatin    size 0 capsules for oral 
administration. Each of the strengths of pi[INVESTIGATOR_399199] a different color capsule (see below).  
Proprietary Information of MD Anderson
28 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 1. 15mg: Green 
2. 30mg: Gray 
Capsules consist of pi[INVESTIGATOR_399200]: lactose, microcrystalline cellulose, 
croscarmellose sodium, poloxamer 188, and magnesium stearate. 
Pi[INVESTIGATOR_399201] (GMP). 
Pi[INVESTIGATOR_399202]-density 
polyethylene (HDPE) caps, supplied in individual cardboard boxes. Each box and drug unit will be numbered to allow complete drug  accountability. 
All drugs will be supplied with Certificates of Analysis.  Packaging and labeling will be in accordance with applicable local  
regulatory requirements and applicable GMP Guidelines. 
 It is stored at room temperature (≤  25°C/77ºF). 
Please note that drug disposal will be on site according to MDACC Institutional policy.   
 6.2.1 D
OSAGE AND ADMINISTRATION  
Pi[INVESTIGATOR_399203] a dose of  either 30 mg, 45 mg, or 60 mg twice daily (BID) continuously, based on 
RP2D. Starting dose level for phase [ADDRESS_503162] will be              instructed to swallow the capsules without 
biting into breaking or opening them, or attempting to dissolve the content in water prior to taking them. 
   
A time window of 12 ± 3 hours between the administration of the morning and evening dose of pi[INVESTIGATOR_399204].    
Proprietary Information of MD Anderson
29 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Table 1: Trial Treatments  and Description  
Product Dose  Dose 
Frequency  Route of 
Administration  Appearance  Storage 
Conditions 
(per label)  
BINTRAFUSP 
ALFA 
(M7824)   1200 
mg Every 2 
Weeks  IV Infusion   2oC – 8oC 
Pi[INVESTIGATOR_399163]  60mgA Twice Daily  Oral   
A=DEPENDING ON THE PHASE OF THE STUDY THE PARTICIPANT IS PARTICIPATING IN , THEY COULD RECEIVE 30-60MG OF THE DRUG .   
 
6.2.[ADDRESS_503163] been reported as 
anaphylaxis, anaphylactoid reactions, and    cytokine release syndrome, among other terms used. IRRs are   risks (adverse  reactions) for Bintrafusp Alfa  (M7824) , and the                                precautions and management are 
provided in Table 6 . 
A. Signs and symptoms of infusion related reactions (IRRs) including hypersensitivity include but not limited to pyrexia, chills , 
flushing, hypotension, dyspnea, wheezing, back pain, abdominal pain, and urticaria, were reclassified as risks (adverse react ions). 
 
B. Management --Patients who experience infusion- associated symptoms may be treated symptomatically with acetaminophen, 
ibuprofen, diphenhydramine, and/or cimetidine or another H2 receptor antagonist, as per standard practice . Serious 
Proprietary Information of MD Anderson
30 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 infusion- associated events manifested by [CONTACT_27926], hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen 
saturation, or respi[INVESTIGATOR_40802]. 
 
 
 
 
  
Immune -Mediated Pneumonitis  
 
Lung Toxicities 
Pneumonitis  
Deﬁnition: Focal or diffuse inﬂammation of the lung parenchyma (typi[INVESTIGATOR_107953]ﬁed on CT imaging)  
No symptomatic, pathologic, or radiographic features are pathognomonic for pneumonitis 
Diagnostic work-up 
Should include the following: CXR, CT, pulse oximetry 
For G2 or higher, may include the following infectious work-up: nasal swab, sputum culture and 
sensitivity, blood culture and sensitivity, urine culture and sensitivity 
Grading  Management  
G1: Asymptomatic, conﬁned to one lobe of the 
lung or <  25% of lung parenchyma, clinical or 
diagnostic observations only Continue I mmu n e Checkpoint inhibitor (ICPi)   
If clinically indicated. Monitor participants 
weekly or more frequently as needed with 
history, physical examination and pulse 
oximetry;  may also offer CXR. May offer one 
repeat CT scan in 3 to 4 weeks; in patients who have had baseline testing, may offer a repeat 
spi[INVESTIGATOR_038]/DLCO in 3 to 4 weeks  
Proprietary Information of MD Anderson
31 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Lung Toxicities 
If symptoms appear and/or changes in the 
physical exam are noted, treat as G2  
G2: Symptomatic, involves more than one lobe of 
the lung or 25%- 50% of lung parenchyma, 
medical intervention indicated, limiting 
instrumental ADL  Hold ICPi [INVESTIGATOR_107955] G1 or less 
Prednisone 1 to 2 mg/kg/d and taper by 5 to 10 
mg/wk. over 4 to 6 weeks Consider bronchoscopy 
with BAL  
Consider empi[INVESTIGATOR_399205] 3 days with history and physical 
examination and pulse oximetry, consider CXR; no clinical improvement after 48 to 72 hours of 
prednisone, treat as G3  
G3: Severe symptoms, hospi[INVESTIGATOR_91536], 
involves all lung lobes or 50% of lung 
parenchyma, limiting self -care 
ADL, oxygen indicated 
G4: Life -threatening respi[INVESTIGATOR_7798], 
urgent intervention indicated (intubation) Permanently discontinue ICPi [INVESTIGATOR_107957]; (methyl)prednisolone IV 1 -
2 mg/kg/d; no improvement after 48 hours, may 
add inﬂiximab 5 mg/kg or mycophenolate mofetil 
IV 1 g twice a day or IVIG for 5 days or 
cyclophosphamide; taper corticosteroids over 4-6 weeks  
Pulmonary and infectious disease consults if necessary  
Bronchoscopy with BAL ± transbronchial biopsy 
Patients should be hospi[INVESTIGATOR_399206] (>  12 weeks), according to institutional guidelines 
Consider calcium and vitamin D supplementation with prolonged corticosteroid use 
The role of prophylactic ﬂuconazole with prolonged corticosteroid use (> 12 weeks) remains unclear, 
and physicians should proceed according to institutional guidelines 
Bronchoscopy + biopsy; if clinical pi[INVESTIGATOR_107959], no need for biopsy 
Proprietary Information of MD Anderson
32 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Lung Toxicities 
All recommendations are expert consensus based, with beneﬁts outweighing harms, and strength of 
recommendations are moderate.  
 
Table 2: Treatment Modification for Symptoms of Infusion -related Reactions Caused by [CONTACT_399274] (M7824)  
NCI-CTCAE Grade  Treatment Modification for Bintrafusp 
Alfa (M7824)  
Grade 1 – mild 
• Mild reaction; infusion interruption 
not indicated intervention not 
indicated.  • Decrease the Bintrafusp Alfa  
(M7824) infusion rate by 50% and 
monitor closely for any worsening.  
• The total infusion time for 
Bintrafusp Alfa  (M7824) should 
not exceed 120 minutes 
Grade 2 – moderate  
• Therapy or infusion interruption 
indicated but responds promptly to 
symptomatic treatment (for 
example, antihistamines, NSAIDs, 
narcotics, IV fluids); prophylactic 
medications indicated for ≤ 24 
hours.  • Stop Bintrafusp Alfa  (M7824)  
infusion. 
• Resume infusion at 50% of 
previous rate once infusion- related 
reaction has resolved or decreased to at least Grade 1 in severity, and monitor closely for any worsening 
Grade 3 or Grade  4 – severe or life -
threatening  
• Grade 3: Prolonged (for example, 
not rapi[INVESTIGATOR_399207] • Stop the Bintrafusp Alfa  (M7824)  
infusion immediately and 
disconnect infusion tubing from 
the subject.  
Proprietary Information of MD Anderson
33 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 symptomatic medication and / or 
brief interruption of infusion); 
recurrence of symptoms following 
initial improvement; 
hospi[INVESTIGATOR_50402].  
• Grade 4: Life -threatening 
consequences; urgent intervention 
indicated.  • Subjects have to be withdrawn 
immediately form Bintrafusp Alfa  
(M7824) treatment and must not 
receive any further Bintrafusp Alfa  
(M7824) treatment  
IV = intravenous; NCI -CTCAE = National Cancer Institute – Common Terminology Criteria for Adverse Event; NSAIDs = nonsteroidal 
anti-inflammatory drugs  
Additional Modifications for Subjects with Grade 2 Infusion- related Reactions  
If, in the event of a Grade 2 infusion- related reaction that does not improve or w orsens after implementation of the modifications 
indicated in Table 2 (including reducing the infusion rate by 50%), the Principal Investigator [INVESTIGATOR_399208]. At the next infusion, the Principal Investigator [INVESTIGATOR_399209] H2- blocker antihistamines (for example, famotidine or ranitidine), in addition to premedication, for select subjects. 
However, prophylactic steroids are NOT permitted. If the subject has a second infusion- related r eaction Grade ≥ 2 on the slower infusion 
rate, with or without the addition of further medication to premedication, the infusion should be stopped and the investigator may consider withdrawal of this participant from the study. 
Immune -Related Adverse Events  
For reporting irAE severity/toxicity grading, refer to CTCAE v.5 toxicity grading system. For treatment management of irAE per CTCAE v.5 criteria, refer to American Society of Clinical Oncology (ASCO) Clinical Practice 
Guidelines and National Comprehensive Cancer Network irAE Management Guidelines.  Refer to Appendix 6 and 7.   
The recommendations for irAE management, in accordance with the joint American Society of Clinical Oncology Clinical Practice  
Guidelines (Brahmer, 2018) and National Comprehensive Cancer Network (NCCN Guidelines®), are listed in Appendix 6.  
Proprietary Information of MD Anderson
34 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Treatment of irAEs is mainly dependent upon severity as defined by [CONTACT_12134] -CTCAE v5.0. In general, management by [CONTACT_3989] v5.0 grading, 
as per ASCO, is listed below: 
• Grade 1: study treatment should be continued with close monitoring, with the exception of some neurologic, hematologic, and c ardiac 
toxicities.  
• Grade 2: study treatment may be suspended for most Grade 2 toxicities, with consideration of resuming when symptoms revert to  
Grade 1 or less. Corticosteroids may be administered (initial dose of 0.5 to 1 mg/kg/day of prednisone or equivalent).  
• Grade 3: study treatment is generally suspended and the high- dose corticosteroids (prednisone 1 to 2 mg/kg/day or 
methylprednisolone 1 to 2 mg/kg/day) treatment should be initiated. Corticosteroids should be tapered over the course of at l east 4 
to 6 weeks. Some refractory cases may require infliximab or other immunosuppressive therapy.  
• Grade 4: in general, permanent discontinuation of study treatment is recommended, with the exception of endocrinopathies that  have 
been controlled by [CONTACT_108089]. 
For organ/system specific management guidelines, review ASCO guideline tables in Appendix 7. 
Since inhibition of PD -L1 stimulates the immune system, irAEs may occur. Treatment of irAEs is mainly dependent upon severity (NCI -
CTCAE grade):  
• Grade 1 to 2: treat symptomatically or with moderate dose steroids, more frequent monitoring 
• Grade 1 to 2 (persistent): manage similar to high grade AE (Grade 3 to 4) 
• Grade 3 to 4: treat with high dose corticosteroids 
Anemia  
Anemia is considered a important identified  risk based on toxicological findings with Bintrafusp Alfa  (M7824) in cynomolgus monkey 
indicating a decrease in Hgb, RBCs, and hematocrit that was fully reversible or showed a substantial trend toward recovery. N otably, 
there are many reasons for anemia in patients with advanced cancer, which is why a thorough investigation of new anemia cases of 
unspecified etiology is requested.  
 Risk management measures in addition to routine laboratory tests will include: 
Proprietary Information of MD Anderson
35 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 • Subjects must enter the study with Hgb values at least 9 g/dL, independent of recent (≤ 14 days) packed red blood cell transfusion 
and/or use of an erythropoietin- stimulating agent.  
• Routine monitoring of Hgb will be performed every 2 weeks (prior to treatment).Instructions for study treatment 
discontinuation or modification in case of anemia will be provided, briefly described here: In case of any Hgb < 8 g/dL, the Principal Investigator [INVESTIGATOR_399210], including Coombs, haptoglobin, indirect bilirubin and peripheral smear, and prothrombin time (PT), activated partial thromboplastin time (aPTT), international normalized ratio (INR); Hgb and he matocrit are to be closely monitored. 
• For new anemia events assessed as treatment -related, items queried may include but are not limited to detailed relevant past 
medical and treatment history, bruising tendency, history of blood transfusions and/or dependency, and a request for an updated eCRF including details such as concomitant medications, all laboratory data, updated dosing information and recent tumor evaluation scans.  
If a subject experiences significant anemia, then the amount of blood to be drawn may be reduced by [CONTACT_399275] -L1 target occupancy, immunomonitoring, soluble factors, and TGFβ. The decision to reduce the time points 
for these biomarkers will be taken by [CONTACT_079]. 
• Evaluation Guidance of  baseline anemia and Suspected Treatment -related Anemia AEs  
Baseline anemia evaluation (prior to transfusion, if feasible)  
Hemoglobin  and CBC with differential (e.g. MCV, RDW, ANC, hematocrit, reticulocytes 
counts) 
Peripheral blood smear for cell morphological assessment 
Complete metabolic panel including liver panel-LFTs, bilirubin, LDH, renal function, and 
serum folate, B12 values and other chemistries 
Coagulation factors (PT, PTT, INR)  
Urinalysis including culture 
Iron panel (TIBC, ferritin, Fe) 
Proprietary Information of MD Anderson
36 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 TSH/hormonal panel  
Fecal -occult blood testing 
haptoglobin  
Further recommendation based on suspected etiology (in addition to baseline anemia 
testing)  
Unknown etiology, 
suspect possible 
hemolysis Coombs test, fibrinogen, d -dimer  
Consider hematology consultation. 
Consider blood transfusion at clinical discretion.  
Unknown  etiology, 
suspect possible bleeding Consider blood transfusion at clinical discretion.  
Consider surgical/interventional radiology consultation. 
Consider imaging, as clinically indicated (e.g. FAST scan, CT 
scan, MRI, angiography). 
Consider endoscopy (upper/lower)  
Unknown etiology 
despi[INVESTIGATOR_397268]-up Hematology consultation  
Consider bone marrow aspi[INVESTIGATOR_1516]/morphologic evaluation  
 
Rash with Hyperkeratosis / Keratoacanthoma / Squamous Cell Carcinoma of the Skin 
Treatment -related skin lesions with hyperkeratosis, keratoacanthoma, cutaneous squamous cell carcinoma possibly due to TGFβ 
inhibition are important identified risks (adverse reactions) for Bintrafusp Alfa  (M7824) . They have been manageable and did not lead 
to permanent discontinuations in Bintrafusp Alfa  (M7824) studies. Patients with known Lynch Syndrome who develop 
Proprietary Information of MD Anderson
37 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 keratoacanthomas on study are encouraged to be evaluated for Muir Torre syndrome.  Monitoring will include skin assessments a s 
defined in the Schedules of Assessments  (Section 8 .0), with biopsy of suspi[INVESTIGATOR_148352]. Management should be discussed with the 
Principal Investigator [INVESTIGATOR_2394] a case-by- case basis. Dermatological consults should be requested as needed in the event that possible drug-
related skin toxicity is suspected by [CONTACT_093]. 
Impaired Wound Healing  
Due to the involvement of TGFβ in repair of skin and other tissue injuries, impaired wound healing is considered a n important potential 
risk. For any surgeries conducted post -treatment initiation, surgical wound healing will be closely monitored. Management should be 
discussed with the Principal Investigator [INVESTIGATOR_2394] a case -by-case basis. Dermatological consults should be requested as needed. 
Bleeding Adverse Events 
Bleeding Adverse Events  
• Bleeding adverse events are considered important identified risk for bintrafusp alfa. 
• In general, mild and moderate mucosal bleedings resolve without discontinuation of treatment.  
• These events may include, but are not limited to the following:  
o Epi[INVESTIGATOR_3940]  
o Hemoptysis  
o Gingival bleeding  
o Hematuria  
Non-tumor Bleeding  
Grading  Management  
Grade 2  • If resolves to Grade ≤  1 by [CONTACT_108091], study intervention may be 
continued  
• If not resolved to Grade ≤  1 by [CONTACT_108091], but is manageable and /or not 
clinically relevant, consult Medical Monitor to 
assess if clinically reasonable to administer the 
following infusion.  
Grade 3  
 • Permanently discontinue treatment unless an alternative explanation can be identified (such as concomitant use of antithrombotic agents, 
traumatic events, etc.)  
Proprietary Information of MD Anderson
38 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 • In case of alternative explanations, hold study 
treatment until the event recovers to Grade ≤  1 
Grade 4  • Treatment must be permanently discontinued if 
no alternative explanation is identified.  
Tumor Bleeding  
Grade ≥ 2 • Study treatment must be held till the event 
recovers to Grade ≤  1 
• Permanently discontinue treatment if the Investigator considers the participant to be at risk for additional severe bleeding.  
 
Ocular toxicity  
If a subject experiences Retinal Vein Occlusion  the pi[INVESTIGATOR_399211]. Appropriate  follow -up and 
treatment measures must be taken by [CONTACT_399276].  If a subject shows a symptomatic serous retinal detachement : Withhold treatment for ≤3 weeks , if improved to grade 0/1, resume at 
same dose level . If not improved, resume at the lower dose level or permanently discontinue pi[INVESTIGATOR_399212]. Management should 
be discussed with Principal Investigator [INVESTIGATOR_399213]. Elevation of Serum Creatine Phosphokinase 
Subjects should be advised to immediately report any muscle pain, tenderness or weakness, or any  macroscopic myoglobinuria (tea -
colored urine). Subject -reported muscle symptoms or urine  discoloration should be investigated with CPK measurements and urinalysis 
for myoglobinuria.  
CPK measurement should be at screening and every 4 weeks; at any time for symptomatic patient s.  Assess with differentiation if 
irAE or due to P imasertib; including DD presence/absence of further symptomatic findings: full history (including conmeds), 
exercises, training, muscular injury, muscular injections, CPK isoenzymes, and etc.   
 
Proprietary Information of MD Anderson
39 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 CPK increase G4: Withhold pi[INVESTIGATOR_399214] ≤3 week  
Any CPK elevation and myalgia: If improved to grade ≤3, resume at lower dose level , if not improved within [ADDRESS_503164] will be medically treated for the event.  
If the AE reduces to a lower tolerable grade the study treatment might be resumed in the subsequent cycle. If the AE remains the same 
in spi[INVESTIGATOR_397269] (second cycle after the AE occurred) a discussion with the Principal Investigator 
[INVESTIGATOR_399215] a possible extension of the dose interruption for up to [ADDRESS_503165] clinical significance do not require dose interruption.  
 6.2.4 SRT
 AND DOSE INTERRUPTIONS  
Proprietary Information of MD Anderson
40 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503166] to hold systemic therapy to receive SRT are allowed to resume therapy within 6 weeks of holding therapy if 
they meet treatment safety parameters.  
 6.2.5 R ESUMPTION OF TREATMENT AFTER DOSE DELAY  
 Patients may resume therapy at the same doses after dose interruption as long as they continue to meet the treatment safety parameters.  
 6.2.6 C
ONCOMITANT AND EXCLUDED THERAPI[INVESTIGATOR_399216] . Medications or vaccinations specifically prohibited in the exclusion criteria  
(See  section 5.2) are not allowed during the ongoing trial. The following are also prohibited and are not allowed:  
• Any traditional Chinese medication used as anticancer treatment (regardless of the type of cancer) is prohibited. Traditional  
Chinese medication for indications other than anticancer treatment, such as supportive care, may be administered at the discr etion  of the 
Investigator.  
• Herbal remedies with immunostimulating properties (e.g., mistletoe extract) or known to potentially interfere with major orga n 
function (e.g., hypericin). 
If there is a clinical indication for any medication or vaccination specifically prohibited during the trial, discontinuation from trial therapy 
or vaccination may be required. The final decision on any supportive therapy or vaccination rests with the principal investigator [INVESTIGATOR_1238]/or 
the subject's primary physician. However, the decision to continue the subject on trial therapy or vaccination schedule requi res the 
mutual agreement of the principal investigator, and the subject. 
 6.2.[ADDRESS_503167]’s welfare may be administered at the discretion of the 
Principal Investigat or in keepi[INVESTIGATOR_77981]. All concomitant medication will be recorded on the 
eCRF including all prescription, over -the- counter (OTC) products, herbal supplements, and IV medications and fluids. If changes occur 
during the trial period, documentation of drug dosage, frequency, route, and date should also be included on the eCRF.  
Proprietary Information of MD Anderson
41 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503168] dose of trial treatment should be recorded for SAEs 
and ECIs. 
 6.2.8 P ERMITTED THERAPI[INVESTIGATOR_5165] : SRT  
For patients that are deriving clinical benefit from protocol treatment, but having evidence of progression in brain lesions that are 
amenable to SRS, treatm ent with SRS is allowed and patients can remain on systemic therapy. Patients will be censored for brain 
metastasis response unless one measurable lesion remains unirradiated. Patients will continue to be monitored for intracrania l PFS.   
 6.2.9 P ERMITTED THERAPY FOR BRAIN EDEMA  
  Patients that develop neurologic symptoms suspected to be secondary to brain edema are allowed to receive steroids as 
clinically indicated.  
 6.2.10  PERMITTED THERAPY : BRAIN SURGERY  
  Patients that develop an indication for brain surgery will be managed as clinically indicated. They will be assessed post- operatively in the setting of the MD Anderson Brain Metastasis Clinic (or similar multi- disciplinary setting) to determine whether 
resuming systemic therapy on protocol is warranted. The same dose interruptions and treatment resumption criteria that apply to SRT 
will apply to neurosurgical interevention as well. 
7.[ADDRESS_503169] had chemotherapy, radiotherapy (other than palliative 
radiotherapy delivered in a normal organ- spearing technique ), major surgery, or received another investigational agent within [ADDRESS_503170] not be administered during the trial: 
Proprietary Information of MD Anderson
42 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 • Immunotherapy including interferon, immunosuppressive drugs (for example, chemotherapy or systemic corticosteroids except 
for short term treatment of allergic reactions, endocrine replacement therapy at low dose prednisone [≤ 10 mg daily] or equivalent, or  for the treatment of irAEs or other appropriate short term steroid use), or other experimental pharmaceutical 
products. Short term administration of systemic steroid or other immunosuppressant such as infliximab or mycophenolate (that is, for allergic rea ctions or the management of irAEs) is allowed. Steroids with no or minimal systemic effect (topi[INVESTIGATOR_2855], inhalation) 
are allowed.  
• Adefovir. 
• Prophylactic use of corticosteroids for infusion related reactions is prohibited. 
• Any live vaccine therapi[INVESTIGATOR_148356]. Administration of inactivated vaccines is allowed (for 
example, inactivated influenza vaccines  
or approved SARS -COV -2 vaccines ). 
• Vaccines will be allowed and will require one week between administration and treatment.   
If the administration of a non-permitted concomitant drug becomes necessary during the tr ial, the subject will be withdrawn from trial 
treatment (the Principal Investigator [INVESTIGATOR_399217]). 
Medications other than those specifically excluded in this trial (as outlined in this section) may be administered for the management of 
symptoms associated with the administration of Bintrafusp Alfa  (M7824) as required. These might include analgesics, anti -emetics, 
antihistamines, diuretics, anti-anxiety medications, and medication for pain management, including narcotic agents.  
Any additional concomitant therapy that becomes necessary during the trial and any change to concomitant drugs must be recorded in the corresponding section of the eCRF (Prometheus) and medical record, noting the name, dose, duration, and indication of each drug. 
The following non-drug therapi[INVESTIGATOR_397267] (and within 28 days before the start of trial treatment): 
• Major surgery (excluding prior diagnostic biopsy).Herbal remedies with immunostimulating properties (for example, mistletoe 
extract) or known to potentially interfere with major organ function (for example, hypericin) 
• Subjects should not abuse alcohol or other illicit drugs during the trial 
Drugs known to prolong the QT interval must be used with caution if they cannot be avoided. The list of the drugs in question is given 
at the following web address: http://crediblemeds.org/everyone/composite- list-all-qtdrugs/?rf=All  
Proprietary Information of MD Anderson
43 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Furthermore, caution should be exercised when starting or increasing the dose of any medication that is considered to be associated with 
muscle toxicity (e.g., 3-Hydroxy-3-Methylglutaryl- Coenzyme A [ HMG CoA] reductase inhibitors [statins]).  
Interactions 
• Pi[INVESTIGATOR_399218] a substrate of Cytochrome P450 (CYP) Isoforms CYP3A4 and CYP2C19, and may possibly inhibit CYP2C9. 
Based on this, it was concluded that concomitant administration with the following drugs should be used with caution or avoided if possible: 
• Strong inhibitors of CYP3A4 
• Strong inducers of CYP3A4 
• Strong inhibitors of CYP2C19 
• Substrates of CYP2C9 with a narrow therapeutic index 
A list of drugs that should be used with caution or avoided is presented can be found here: 
https://drug -interactions.medicine.iu.edu/Main -Table.aspx  
SPECIAL PRECAUTIONS  
As a routine precaution, subjects all enrolled in this trial must be observed for [ADDRESS_503171] two doses of treatment with Bintrafusp Alfa  (M7824) . If no medical  
problems arise during the first two treatments, then the [ADDRESS_503172] dose 
of treatment. At all times during Bintrafusp Alfa  (M7824) treatment, immediate emergency treatment of an infusion- related reaction or 
a severe hypersensitivity reaction according to institutional standards must be assured. In order to treat possible anaphylactic reactions, 
for instance, dexamethasone 10 mg and epi[INVESTIGATOR_75447] a 1:1000 dilution or  equivalents should always be available along with equipment 
for assisted vent ilation.  
Proprietary Information of MD Anderson
44 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Infusion of Bintrafusp Alfa  (M7824) will be stopped in case of Grade ≥ 2 hypersensitivity, inflammatory response, or anaphylactic 
reaction. The treatment recommendations for infusion- related reactions and severe hypersensitivity reactions according to the NCI are 
outlined in Section 6.2.3. 
Principal Investigators should also monitor subjects closely for potential irAEs (described in Section 6.2.3), which may become 
manifest after several weeks of treatment. Such events may consist of persistent  rash, diarrhea and colitis, autoimmune hepatitis, 
arthritis, glomerulonephritis, cardiomyopathy, or uveitis and other inflammatory eye conditions.   
 
         
 
         
 
  
Proprietary Information of MD Anderson
45 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 8.0 S CHEDULE OF ASSESSMENTS  
TABLE 3 SCHEDULE OF ASSESSMENTS  
Trial Period:  Screening Phase   
 
Treatment Cycles a End of 
Treatment Post-Treatment  
Treatment Cycle/Title : Screening  
 C1
D1  
C2 
D1  
3 4 To be 
repeated 
beyond 8 
cycles  
Discontinuati
on Safety  
Follow-
up Follow 
Up  
Visits b Survival 
Follow-
Upp C1 
D15 C2 
D15 5 6 7 8 
Scheduling Window (Days): -28 to -1 
   
± 
3  
± 
3 ± 
3 ± 
3 ± 
3 ± 
3 ± 
[ADDRESS_503173] 
discontin
uation 
± [ADDRESS_503174] 
discontinu
ation  
± 7 Every 12 
weeks  
± 7  
Administrative Procedures  
Informed Consent  X               
Inclusion/Exclusion Criteria  X               
Demographics and Medical 
History  X               
Prior and Concomitant 
Medication Review  X X X X X X X X X X X X    
Trial Treatment 
Administration  c  X X X X X X X X X X     
Proprietary Information of MD Anderson
46 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Trial Period:  Screening Phase   
 
Treatment Cycles a End of 
Treatment Post-Treatment  
Treatment Cycle/Title : Screening  
 C1
D1  
C2 
D1  
3 4 To be 
repeated 
beyond 8 
cycles  
Discontinuati
on Safety  
Follow-
up Follow 
Up  
Visits b Survival 
Follow-
Upp C1 
D15 C2 
D15 5 6 7 8 
Scheduling Window (Days): -28 to -1 
   
± 
3  
± 
3 ± 
3 ± 
3 ± 
3 ± 
3 ± 
[ADDRESS_503175] 
discontin
uation 
± [ADDRESS_503176] 
discontinu
ation  
± 7 Every 12 
weeks  
± [ADDRESS_503177]-study anticancer therapy 
status               X X 
Survival Status   
             X 
Clinical Procedures/Assessments  
Review Adverse Events   X X X X X X X X X X X X X X 
Physical Examination  X X X X X X X X X X X X  X  
Vital Signs, Weight, and 
Heightn X X X X X X X X X X X X  X  
Electro cardiogram (12 -Lead 
ECGs)  X               
ECHO/MUGA  X   X   X  X  X X    
Ophthalmological Examl X      X   X  X    
Proprietary Information of MD Anderson
47 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Trial Period:  Screening Phase   
 
Treatment Cycles a End of 
Treatment Post-Treatment  
Treatment Cycle/Title : Screening  
 C1
D1  
C2 
D1  
3 4 To be 
repeated 
beyond 8 
cycles  
Discontinuati
on Safety  
Follow-
up Follow 
Up  
Visits b Survival 
Follow-
Upp C1 
D15 C2 
D15 5 6 7 8 
Scheduling Window (Days): -28 to -1 
   
± 
3  
± 
3 ± 
3 ± 
3 ± 
3 ± 
3 ± 
[ADDRESS_503178] 
discontin
uation 
± [ADDRESS_503179] 
discontinu
ation  
± 7 Every 12 
weeks  
± 7  
ECOG Performance Status  X X X X X X X X X X X X   X X 
Neuro -function (NANO) X X  X  X X X X X X X    
Neuropsych Testingo/ 
Neurocognitive Testing X     X          
Laboratory Procedures/Assessments: analysis performed by [CONTACT_131002] – Urine or 
Serum - HCG d X   X  X X X X X X X    
Coagulation e X               
CBC with Differentialk X X X X X X X X X X X X  X  
CMPm X X X X X X X X X X X X  X  
Urinalysis X   X  X X X X X X X    
Proprietary Information of MD Anderson
48 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Trial Period:  Screening Phase   
 
Treatment Cycles a End of 
Treatment Post-Treatment  
Treatment Cycle/Title : Screening  
 C1
D1  
C2 
D1  
3 4 To be 
repeated 
beyond 8 
cycles  
Discontinuati
on Safety  
Follow-
up Follow 
Up  
Visits b Survival 
Follow-
Upp C1 
D15 C2 
D15 5 6 7 8 
Scheduling Window (Days): -28 to -1 
   
± 
3  
± 
3 ± 
3 ± 
3 ± 
3 ± 
3 ± 
[ADDRESS_503180] 
discontin
uation 
± [ADDRESS_503181] 
discontinu
ation  
± 7 Every 12 
weeks  
± 7  
Lactate dehydrogenase 
(LDH)  X   X  X X X X X X X    
T3, FT4 and TSH  X X    X  X  X  X    
Creatinine Phosphokinase  X X  X  X X X X X X X    
HIV, HBV, HCV Testing  X               
Efficacy Measurement  
Tumor Imaging & 
Assessment of disease: MRIf  X   
 X  X X X 
 X 
 X    
Tumor Imaging & Assessment of disease: CT’s
f X   
  X   
X   
X      
Tumor Biopsies/Archival Tissue Collection/Correlative Studies Blood  
Proprietary Information of MD Anderson
49 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Trial Period:  Screening Phase   
 
Treatment Cycles a End of 
Treatment Post-Treatment  
Treatment Cycle/Title : Screening  
 C1
D1  
C2 
D1  
3 4 To be 
repeated 
beyond 8 
cycles  
Discontinuati
on Safety  
Follow-
up Follow 
Up  
Visits b Survival 
Follow-
Upp C1 
D15 C2 
D15 5 6 7 8 
Scheduling Window (Days): -28 to -1 
   
± 
3  
± 
3 ± 
3 ± 
3 ± 
3 ± 
3 ± 
[ADDRESS_503182] 
discontin
uation 
± [ADDRESS_503183] 
discontinu
ation  
± 7 Every 12 
weeks  
± 7  
Archival Tissue g X               
Serial Biopsy h X   x    X        
Blood /Tissue  Collection X   X  X X X X X X     
Correlative Studies  j X   X    X    X    
PK and ADA   X  X  X   X   X X   
CSFi (optional) X X    X          
 
     
Proprietary Information of MD Anderson
50 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 a  Cycles are 4 weeks (28 days) in duration 
b  Patients who discontinue trial treatment for reasons other than disease progression will move into the Follow -Up phase. Patients 
will be seen every [ADDRESS_503184] year, then every 12 weeks thereafter up to 2 years. 
c   M7824 1200 mg every 2 weeks. Pi[INVESTIGATOR_399219] 60mg twice daily.  (30 to 60 mg depending on phase) d  See Page [ADDRESS_503185] dose of drug.   
e  Prothrombin time/International Normalized Ratio, Activated Partial thromboplastin time.  
f  MRI Scan will be performed every [ADDRESS_503186] 16 weeks, then every 8 weeks until progression or discontinuation of 
study treatment, whichever comes later. Imaging window is ± [ADDRESS_503187] will be performed every 8 weeks until progression of discontinuation of study treatment, whichever comes 
later. Imaging window is ± [ADDRESS_503188]/abdomen/pelvis or PET -CT is not already performed as standard of care per Schedule of 
Assessments in Section [ADDRESS_503189] tissue collected. See Section 8.8.   
i  Cerebrospi[INVESTIGATOR_399220]. S ee section 8.7.3 for additional details. 
j  See Section 8.7.   k  CBC & CMP is done every 2 weeks (+/- 7 days) prior to infusion.   
l   Patients will have ophthalmological evaluation at baseline and every 12 weeks. See section 8.3. 
while receiving protocol therapy  
m  Serum chemistry includes the tests listed (glucose, BUN, creatinine, sodium, potassium, magnesium, chloride, bicarbcionate, calcium, phosphorus, total and direct bilirubin, ALT, AST, ALP, LDH, total protein, albumin, CPK, and uric acid). CMP is done every 2 weeks prior to infusion. 
n  Height only taken at Screening o  There will also be a Neurocognitive exam at the 3 -month mark 
p  A follow up call will be done at 90 days to assess patient safety.  
Proprietary Information of MD Anderson
51 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503190] dose of trial treatment, new clinically significant abnormal findings should be recorded as AEs.  
  8.1.2 D
IRECTED PHYSICAL EXAM  
The Principal Investigator [INVESTIGATOR_399221] a directed physical exam as clinically indicated prior to 
the administration of the trial treatment. New clinically significant abnormal findings should be recorded as AEs. 
 8.1.3 V ITAL SIGNS  
Vital signs include temperature, pulse, respi[INVESTIGATOR_697], weight and blood  pressure. The Principal Investigator [INVESTIGATOR_399222], prior to the administration of each dose of trial treatment and   during 
the follow -up period as specified in the Trial Flow Chart (Section 8.0). Height will be measured at Screening. 
 8.1.[ADDRESS_503191] 1.1 while other measurement criteria will be utilized as secondary endpoints including  iRANO criteria (See Appendix 1 ).Quantitative imaging changes on multiparametric 
MRI will be captured to determine early biomarkers of immune response. Standard of care brain MRI with intraven ous 
gadolinium contrast and contrast enhanced CT chest/abdomen/pelvis or PET- CT, as clinically indicated, will be used to 
assess both intracranial and extracranial disease at Screening and every [ADDRESS_503192] year, then every 12 weeks until progression or discontinuation of study treatment, whichever comes  
Proprietary Information of MD Anderson
52 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 later. Imaging window is ± [ADDRESS_503193]/abdomen/pelvis or PET-CT is not already performed as standard of care per Schedule of 
Assessments in Section 8.0, the principal investigator [INVESTIGATOR_399223] s of the patient.  
8.[ADDRESS_503194] be representative formalin -fixed paraffin -embedded  
                        (FFPE) tumor specimens in paraffin blocks (preferred) or at least                          [ADDRESS_503195] tissue collected pretreatment and at Cycle 2 ( 4 weeks after the 
start of treatment). An additional optional biopsy may be collected at Cycle 5, if accessible, but is not required. All 
biopsies are optional for enrollment, but highly encouraged for pretreatment and Cycle 2.  If standard of care biopsies 
are required, additional, optional tissue may be acquired as part of this protocol.  Acceptable samples include core -needle 
biopsies for deep tumor tissue (minimum of three cores) or excisional, incisional, or punch biopsies for cutaneous, 
subcutaneous, or mucosal lesions. 
  For core -needle biopsy specimens, at least three cores should be   
             submitted for evaluation.  Cores will be distributed to FFPE and               snap  frozen equally.   
 8.3 OPHTHALMOLOGY  
Proprietary Information of MD Anderson
53 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503196] procedures at Screening. Clinically significant abnormal findings should be recorded as medical history.  
Clinically significant abnormal findings seen on the follow-up ECGs should be recorded as adverse events. 
8.5.1   E CHO/MUGA  
An ECHO/MUGA will be done at baseline and every 2 months.   Please refer to Table 3.0 for additional information.  
Clinically significant abnormal findings  seen on the follow-up ECHOs  should be recorded as adverse events. 
8.6 N
EUROLOGICAL FUNCTION TESTING  
Proprietary Information of MD Anderson
54 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Neurologic functioning will be evaluated using NANO. This objective and quantifiable assessment will evaluate nine major domains 
for subjects with brain tumors. The domains include: gait, strength, ataxia, sensation, visual field, facial strength, langua ge, level o f 
consciousness, behavior and overall. Each domain is rated on a scale of [ADDRESS_503197] 
severity. A given domain should be scored non- evaluable if it cannot be accurately assessed due to preexisting co nditions, co -morbid 
events and/or concurrent medications. The evaluation is based on direct observation/testing performed during routine office visits. The NANO scale will be completed by [CONTACT_458] [INVESTIGATOR_399224] 1 Week 1 (baseline) and then at the time points indicated in on the schedule of events.  
Neuropsychological testing will be performed with a standardized battery routinely used to assess patients with brain metasta ses at 
MDACC, including in the previously published Chang et al. trial [55].  This evaluation will be performed by a trained psycho metrist 
under the supervision of [CONTACT_399298], a licensed, board certified clinical neuropsychologist in the Department of Neuro-Oncology. The 
following tests were selected because they are widely used, standardized psychometric instruments that have been shown to be sensitive to changes in neurologic disease as well as treatment effects of cancer treatment in other clinical trials.   Normative data have been published for all tests that take into account age, education, sex and handedness, where appropriate. These tests were also selected to minimize practice effects associated with repeated administration. The memory test has six alternate forms and th e verbal 
fluency test has two alternate forms. The other tests measure motor and information processing speed and are relatively resistant to the effects of practice.  
 
The total time for neuropsychological testing, including the quality of life (QOL) and symptom measures, is about [ADDRESS_503198] Administration 
Time 
(minutes)  
Memory  Hopkins Verbal Learning Test -
Revised (HVLT -R) [ADDRESS_503199], Part A  
WAIS -IV Coding  3 
3 
Proprietary Information of MD Anderson
55 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503200] Association 
(COWA)  [ADDRESS_503201]  5 
   
PRO  MD Anderson Symptom Inventory – 
Brain Tumor  10 
   
 
ECOG Evaluation  
Eastern Cooperative Oncology Group (ECOG) Evaluation will be performed at Screening and at each cycle for every patient.  The 
principal investigator [INVESTIGATOR_399225] (see Appendix 4) at screening, additional time points for 
assessment of ECOG must be performed.  
8.7 R ESEARCH SAMPLE COLLECTION  
Samples for correlative studies may  be collected as specified in the study calendar, processed and/or stored for analysis with 
optional subject consent. All tissue and resulting data will be de-identified and may be shared between MD Anderson and the study supporter ( EMD ). All samples and data will be tracked utilizing a unique research tracking number that will not be 
related to any patient identifying information. The sample collections will be reported in the database and a source document will be printed for monitorin g purposes. Upon termination of the study, any remaining blood and tissue samples will be 
transferred and stored in the Melanona Tissue Bank (MelCore) for future use with an IRB approved protocol. 
Biospecimens will be collected accordint to the study calendar to evaluate the immunological effect of the treatment and SRS. 
Methods to evaluate this include but may not be limted to:  
• FACS on isolated PBMCs  
• Serum/plasma collection to assess cir culating inflammatory cytokines 
• Single sta in IHC.  Markers include, but are not limited to: CD3, CD4, CD8, CD20 (B cell), CD1a (DC), CD11c 
(myeloid lineage), Granzyme B (cytotoxic CTLs and NK cells) FOXp3 (Treg cells) and CD3/CD8/CD45RO memory CTL (as proposed in the “Immunoscore” project); IDO and PD -L1 expression. 
Proprietary Information of MD Anderson
56 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 • Inflammatory expression pattern by [CONTACT_399277], the importance of this evaluation in  our 
proposed study is in delineating the role of mechanisms of resistance assessed in extracranial metastatic melanoma tissues in  
predicting and describing the patterns of resistance intracranially. It is predicted that the presence or absence of resistance mechanisms extracranially may  predict response and progression- free survival intracranially.  
Tissue availability permitting, we propose broad investigations on tissue biopsies comparing responders and non-responders, including whole exome sequencing, RNA expression analysis, and reverse phase protein array to examine markers of MAP kinase pathway activity, parallel signaling pathways, RTK activation, and pro and anti-apoptotic factors. 
Additionally, we may  assess circulating free DNA from serial plasma/serum samples to determine patterns of response and early 
predictors of resistance.  Finally, single  cell analyses (including  RNA sequencing) may be performed on CSF obtained. 
8.7.[ADDRESS_503202] be representative formalin -fixed  paraffin -embedded  (FFPE) tumor specimens in paraffin blocks (preferred) or at 
least [ADDRESS_503203] tissue collected pretreatment and at Cycle 2 ( 4 weeks after the start of 
treatment). Optional Biopsy may be collected at Cycle 5, if accessible, but is not required. If standard of care biopsies are  required, 
additional, optional tissue may be acquired as part of this protocol. Acceptable samples include core -needle biopsies for deep 
tumor tissue (minimum of three cores) or excisional, incisional, or punch biopsies for cutaneous, subcutaneous, or mucosal lesions.  
Acceptable samples include core needle biopsies for deep tumor tissue or lymph nodes or excisional, incisional, punch, or for ceps 
biopsies for cutaneous, subcutaneous, or mucosal lesions. For core -needle biopsy specimens, at least three cores should be 
submitted for evaluation.  
 
8.7.2 B LOOD  
Local laboratory assessments will include the following: 
Proprietary Information of MD Anderson
57 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 • Hematology (CBC, including RBC count, hemoglobin, hematocrit, WBC count, percent and absolute differential [neutrophils, 
bands, eosinophils, lymphocytes, monocytes, basophils, and other cells], and platelet count) 
• Serum chemistries (glucose, BUN, creatinine, sodium, potassium, magnesium, chloride, bicarbonate, calcium, phosphorus, total and direct bilirubin, ALT, AST, ALP, LDH, total protein, albumin, CPK , and uric acid) 
• Coagulation (aPTT and INR) 
• Pregnancy test (for women of childbearing potential, including women who have had a tubal ligation) 
• Urinalysis (specific gravity, pH, glucose, protein, ketones, and blood) 
• Serum samples for auto -
 antibody testing  (PK and ADA samples are all serum) 
PK 
PRIOR TO INFUSION AND IMMEDIATELY AFTER INFUSION (EOI)  
Cycle 1, day 1 and cycle 3 day 1 
PRIOR TO INFUSION   only: 
Cycle 2 and Cycle 6 OR end of treatment (whatever comes first) and followup visit if applicable 
 
ADA:  
PRIOR TO INFUSION only  
Cycle 1, day 1 ( PRETREATMENT); Cycle 3, day 1 and Cycle 6 OR end of treatment (whatever comes first) and followup 
visit if applicable  
 
• Blood samples for biomarker assays (up to 40 mls will be obtained to fulfill correlative biomarker plans) 
Additional Local Testing  
Perform the following tests as indicated in Study Flowchart (Table 3 ) and as clinically indicated.  
• Thyroid function testing (TSH, total T3, and free T4) 
Proprietary Information of MD Anderson
58 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
8.7.3 C EREBROSPI[INVESTIGATOR_399226] (CSF)  
 
CSF may be collected at the time of routine testing for Leptomeningeal disease ( LMD ). Leptomeningeal disease occurs when 
cancer cells migrate from your breast, lung, or some other part of your body to your cerebrospi[INVESTIGATOR_872] (CSF).  CSF may be 
obtained at Cycle [ADDRESS_503204] tissue 
collected.   
 
8.9 T
HERAPY ADMINISTRATION  
 
 
Drug Dose Dose 
Frequen cy Route of 
Administration  Treatment 
Period Use 
Pi[INVESTIGATOR_399163]  30-60 mg  BID Oral Continuously on 
28-day cy cles Experimental 
Bintrafusp 
Alfa 
(M7824) 1200 mg  Every 2 
Weeks  IV Infusion  Once every 2 
Weeks on 28 
day cycles  Experimental 
 8.10 M
ANAGEMENT OF PATIENTS WITH DISEASE PROGRESSION  
In the absence of unacceptable toxicity, patients who meet criteria for    disease progression will be permitted to continue study 
treatment if they meet all of the  following criteria:  
Proprietary Information of MD Anderson
59 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 • Evidence of clinical benefit, as determined by [CONTACT_458] [CONTACT_43638] a review of all available data  
• Absence of symptoms and signs (including laboratory values) indicating unequivocal progression of disease  
• Absence of decline in ECOG Performance Status that can be attributed to disease progression  
• Absence of tumor progression at critical anatomical sites (e.g., leptomeningeal disease) that cannot be managed by [CONTACT_990]-
allowed medical interventions  
  
8.11 S UPPORTIVE CARE GUIDELINES  
Subjects should receive appropriate supportive care measures as deemed necessary by [CONTACT_399278].  Suggested supportive care measures for the management of adverse events with potential immunologic etiology are outlined below. Where appropriate, these guidelines include the use of oral or intravenous treatment with corticosteroids as well as additional anti-inflammatory agents if symptoms do not improve with administration of corticosteroids.   Note that several courses of steroid tapering may be necessary as symptoms may worsen when the steroid dose is decreased. For each disorder, attempts should be made to rule out other causes such as metastatic disease or bacterial or viral infection, which might require additional supportive care. The treatment guidelines are intended to be applied when the principal investigator [INVESTIGATOR_399227] p imasertib and bintrafusp a lfa (M7824).  
Note: if after the evaluation the event is determined not to be related, the principal investigator [INVESTIGATOR_399228] (as outlined below). Refer to Section for dose modification.  
It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or skin photography as part of 
evaluation of the event. 
• Pneumonitis :  
o For Grade 2 events , treat with systemic corticosteroids. When symptoms improve to Grade 1 or less, steroid taper 
should be started and continued over no less than 4 weeks. 
o For Grade 3 -4 events , immediately treat with intravenous steroids.  Administer additional anti- inflammatory measures, 
as needed.  
o Add prophylactic antibiotics for opportunistic infections in the case of prolonged steroid administration. 
• Diarrhea/Colitis :  
Subjects should be carefully monitored for signs and symptoms of enterocolitis (such as diarrhea, abdominal pain, blood or mucus in stool, with or without fever) and of bowel perforation (such as peritoneal signs and ileus).   
Proprietary Information of MD Anderson
60 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 o All subjects who experience diarrhea/colitis should be advised to drink liberal quantities of clear fluids.  If sufficient 
oral fluid intake is not feasible, fluid and electrolytes should be substituted via IV infusion.  For Grade 2 or higher diarrhea, consider GI consultation and endoscopy to confirm or rule out colitis. 
o For Grade 2 diarrhea/colitis,  administer oral corticosteroids.  
o For Grade 3 or 4 diarrhea/colitis,  treat with intravenous steroids followed by [CONTACT_78018].   
o When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. 
• Type 1 diabetes mellitus (if new onset, including diabetic ketoacidosis [DKA]) or ≥ Grade 3 Hyperglycemia, if associated with ketosis (ketonuria) or metabolic acidosis (DKA)  
o For T1DM  or Grade 3 -4 Hyperglycemia 
 Insulin replacement therapy is recommended for Type I diabetes mellitus and for Grade 3- 4 hyperglycemia 
associated with metabolic acidosis or ketonuria.  
 Evaluate patients with serum glucose and a metabolic panel, urine ketones, glycosylated hemoglobin, and C-peptide.  
• Hypophysitis : 
o For Grade 2  events, treat with corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be 
started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered.  
o For Grade 3 -4 events, treat with an initial dose of IV corticosteroids followed by [CONTACT_78019]. When symptoms 
improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be requir ed as the steroid dose is tapered.  
 
• Hyperthyroidism or Hypothyroidism :  
Thyroid disorders can occur at any time during treatment. Monitor patients for changes in thyroid function (at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders. 
o Grade 2  hyperthyroidism events (and Grade 2 -4 hypothyroidism): 
 In hyperthyroidism, non- selective beta -blockers (e.g. propranolol) are suggested as initial therapy. 
 In hypothyroidism, thyroid hormone replacement therapy, with levothyroxine or liothyroinine, is indicated per standard of care.  
o Grade 3 -4 hyperthyroidism  
Proprietary Information of MD Anderson
61 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  Treat with an initial dose of IV corticosteroid followed by [CONTACT_78019]. When symptoms improve to 
Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered.  
• Hepatic : 
o For Grade 2  events, monitor liver function tests more frequently until returned to baseline values (consider weekly). 
 Treat with IV or oral corticosteroids  
o For Grade 3 -4 events, treat with intravenous corticosteroids for 24 to 48 hours.  
o When symptoms improve to Grade 1 or less, a steroid taper should be started and continued over no less than 4 weeks. 
• Renal Failure or Nephritis : 
o For Grade 2  events, treat with corticosteroids. 
o For Grade 3 -4 events, treat with systemic corticosteroids.  
o When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.  
• Ocular reactions:  
o Visual disturbances: for Grade 2 events, pi[INVESTIGATOR_399229], assuming resolution of the event within 2 weeks to Grade 1 or less.  
o In case of visual symptoms but without vision loss, the treatment will not be discontinued. 
• Skin reactions:   
o Early introduction of oral tetracyclines and medium to high potency topi[INVESTIGATOR_35786] (such as 1% hydrocortisone cream with moisteriser) should be initiated in case of Grade [ADDRESS_503205] experiences a severe skin reaction (Grade ≥3), pi[INVESTIGATOR_399230] [ADDRESS_503206] again be interrupted. Treatment may only resume at a lower dose level ([ADDRESS_503207] occurrence) if the reaction has resolved to Grade [ADDRESS_503208] ’S CHART . PATIENTS WHO 
DISCONTINUE STUDY TREATMENT PREMATURELY WILL NOT BE REPLACED .  PATIENTS WHO DISCONTINUE FROM TREATMENT WILL BE 
ASKED TO RETURN TO THE CLINIC NO MORE THAN [ADDRESS_503209] TREATMENT FOR A TREATMENT DISCONTINUATION VISIT .  THE 
Proprietary Information of MD Anderson
62 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 VISIT AT WHICH A RESPONSE ASSESSMENT SHOWS PROGRESSIVE DISEASE MAY BE USED AS THE TREATMENT DISCONTINUATION VISIT 8.13
 W ITHDRAWAL  
 Subjects who discontinue/withdraw from treatment prior to completion of the treatment regimen should be encouraged to continue to 
be followed for all remaining study visits. However, patients have the right to voluntarily withdraw from the study at any time for any reason. In addition, the principal investigator [INVESTIGATOR_346288] a patient from the study at any time. Reasons for withdrawal 
from the study may include, but are not limited to the following:   
• Patient withdrawal of consent at any time  
• Any medical condition, determined by [CONTACT_458] [INVESTIGATOR_399231]’s safety if he or she continues in the study  
• Patient becomes pregnant  
• Principal Investigator [INVESTIGATOR_399232]  
• Patient non- compliance  
 When a subject discontinues/withdraws from participation in the trial, all applicable activities scheduled for the final tria l visit should 
be performed at the time of discontinuation. Any adverse events which are present at the time of discontinuation/withdrawal should be followed in accordance with the safety requirements . 
8.[ADDRESS_503210] visit (LPLV) occurs or the date at which the last da ta 
point required for statistical analysis or safety follow-up is received from the last patient, whichever occurs later. LPLV is expected to occur [ADDRESS_503211] continue to be followed for              collection of outcome and/or survival follow-up data as required by              [CONTACT_122919] [ADDRESS_503212] TO FOLLOW -UP 
Proprietary Information of MD Anderson
63 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503213]’s medical records. If it is determined that the subject has died, the site w ill 
use permissible localmethods to obtain the date and cause of death.   The site staff and PI  [INVESTIGATOR_399233], such as  public health registries and databases, in order to 
obtain updated contact  [CONTACT_3031]. If after all attempts, the subject remains lost to follow -up,   
            then the last known alive date as determined by [CONTACT_458]                 [INVESTIGATOR_399234] i n the subject’s medical records
Proprietary Information of MD Anderson
64 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
9.0  S TATISTICAL CONSIDERATIONS  
 9.1 P HASE I 
 The phase I dose finding part of the study is to determine the recommended phase II dose (RP2D) of Bintrafusp Alfa  (M7824) + Pi[INVESTIGATOR_399187]. The planned DL1 
and DL2 doses are Bintrafusp Alfa  (M7824) flat dose of 1200 mg every 2 weeks and Pi[INVESTIGATOR_399163] 45 
mg PO BID (DL1) and 60 mg PO BID (DL2), and fallback doses DL- 1 are Bintrafusp Alfa  
(M7824) flat dose of 1200 mg every  2 weeks and Pi[INVESTIGATOR_399188] 30 mg PO BID. We will enroll up 
to 12 patients to the Phase I  portion (up to 18 can be enrolled should the trial de- escalate to DL -1). 
The standard “3+3” design will be employed to determine the RP2D. If DL1 is considered too toxic, DL-1 will be explored, if unacceptable toxicity is observed at DL-1, we will consider alternative schedules in discussion with EMD Serono.  Dose limiting toxicity (DLT) is defined as below, including an intracranial and an extracranial DLT. These will be evaluated at [ADDRESS_503214] administration of treatment.  
 Intracranial DLT (T1):   Hypophysitis Grade ≥ 3; or neurologic toxicity Grade ≥3    
            Extracran ial DLT (T2):  Any Grade ≥ 3 adverse event outside CNS that is related  to 
Bintrafusp Alfa  (M7824) or Pi[INVESTIGATOR_399163], occurring during the DLT evaluation  period  
(Exceptions include: grade 3 flu-like symptoms or fever lasting less than a week ,  
Grade 3 fatigue lasting less than a week, local reactions, headaches, nausea, and emesis  leasting 
less than 72 hours , and grade 3 hemoglobin decrease (<8.0g/dL)).  
Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 3  times the upper 
limit of normal (ULN) range and a concomitant elevation of bilirubin [ADDRESS_503215] cohort of 3 patients will be treated at Dose Level 1.  New cohorts of patients will not be 
treated until toxicity has been fully evaluated for all current patients.     The algorithm is as follows at any dose level:   1.  If [ADDRESS_503216] been treated at the lower dose level.  
    
Proprietary Information of MD Anderson
65 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 The recommended phase II dose (RP2D) is defined as the highest dose level with no more than [ADDRESS_503217] data for future larger studies.  Specifically, we would like to estimate time to 
intracranial progression considering death as a competing risk and overall survival time using Kaplan -Meier method, both with 95% confidence interval. 
 Two dose limiting toxicities (DLT) will be monitored separately: intracranial and extracranial DLTs. If there is a high chance that probability of intracranial DLT is found to be > 15%, i.e., Pr(intra -cranial DLT Rate > 15%|Data) > 70%, or the extra- cranial DLT rate of higher than 30%, 
i.e., Pr(extra-cranial DLT Rate > 30%|Data) > 70%, then the regimen will be considered too toxic at current dose. Results should be discussed with EMD Serono to decide if further enrollment should be started at a lower dose level.  Protocol will be amended if necessary.  The window for DLT evaluation will be at 4 weeks after the start of the treatment.  
 Given these rules and the prior for intra-cranial DLT toxicity rate as beta(0.15, 0.85) and extra-cranial DLT toxicity rate as beta(0.3, 0.7), we claim a dose level too toxic if any of the following happens.  Number of patients with intra -cranial DLTs/total of number of patients treated >=3/10, 4/15, 5/20, 
5/25, 6/30; or  Number of patients with extra-cranial DLTs/total of number of patients treated >=4/10, 6/15, 8/20, 9/25, 11/30.  The operating characteristics based on the toxicity stoppi[INVESTIGATOR_182783] 30 patients are in Table 4.  The Bayesian toxicity monitoring rule are calculated by [CONTACT_399279]. The operating characteristics were evaluated using codes written by [CONTACT_399280] D iane Liu.  
 Table 4: Operating Characteristics  (5,000 simulations) 
True Intracranial 
DLT Rate  True Extracranial 
DLT Rate  P (Stop Early)  Average of Expected 
Sample Size  
0.05 0.1 0.03 29 
0.05 0.2 0.17 27 
0.05 0.3 0.50 22 
0.05 0.4 0.82 16 
0.05 0.5 0.97 12 
Proprietary Information of MD Anderson
66 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 0.15 0.1 0.38 25 
0.15 0.2 0.47 23 
0.15 0.3 0.68 19 
0.15 0.4 0.88 14 
0.15 0.5 0.98 11 
0.30 0.1 0.93 14 
0.30 0.2 0.94 13 
0.30 0.3 0.96 12 
0.30 0.4 0.99 11 
0.30 0.5 >0.99  10 
 
9.3 R ESPONSE DEFINITIONS  
 9.3.1 O VERALL SURVIVAL  
Overall survival (OS) is defined as the time from treatment start date to death.  Patients who are 
still alive at the end of the study will be censored.  PFS and OS  will be assessed using the 
Kaplan -Meier method overall and by [CONTACT_9084].  
 9.3.[ADDRESS_503218] 1.1 , will be calculated from 
the time of study enrollment to intracranial progression (event) or the last follow -up date if the 
patient has not developed the intracranial progression yet (censored).  The median time to intracranial progression and intracranial progression free survival rates at specific times will be estimated and reported with 95% confidence interval utilizing the method of Kaplan and Meier. This will serve as the primary  analysis and will be performed overall and within each treatment 
group. Completing risk analysis may be considered by [CONTACT_399281] (e.g. events such as extracranial disease progression, early dropout due to 
toxicity, or death) as competing risks.   
 9.3.[ADDRESS_503219] 1.1 criteria,  will be calculated from 
the time of study enrollment to extracranial  progression (event) or the last follow -up date if the 
patient has not developed the extracranial progression yet (censored). The cumulative incidence 
rate may be estimated by [CONTACT_399282] (e.g. events such as intracranial disease progression, early dropout due to toxicity, or death) as competing risks.   
 9.3.5 E
XTRACRANIAL RESPONSE RATE 
Proprietary Information of MD Anderson
67 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503220] achieved extracranial objective response rate will be reported for each patient. The 
frequency of extracranial objective response will be reported overall and within each treatment group. 
 9.3.6 D
URATION OF RESPONSE  
In patients who achieve extracranial, partial response (PR)or complete response (CR) via RECIST 
1.[ADDRESS_503221] 4 mg of dexamethasone/day for symptom 
management will be considered as requiring high dose steroids. 
 9.3.8 O THER ENDPOINTS  
Descriptive analysis will be provided to summarize the serum, tissue and imaging markers.  The 
relationship between the markers and response and/or toxicities may be evaluated using Kruskal-Wallis test for continuous markers and Fisher’s exact test for discrete mar kers, when appropriate.  
The correlation between the serum/tissue markers and imaging parameters or between any two markers may also be assessed using Spearman correlation.  Given the size of the study, these analysis are exploratory in nature.    Other statistical analysis methods may be applied when fit.  
 The Principal Investigator [INVESTIGATOR_399235]/efficacy summary reports and 
submitting them to the IND office Medical Affairs and Safety Group for review.  These should be submitted as follows:   
• Phase I:  
After the first [ADDRESS_503222] be obtained prior to advancing/changing dose levels.  
• Phase II:  
After the first 10 evaluable patients( including the six treated at RP2D from from phase I) complete 4 weeks of study treatment, and every 5 patients thereafter. Also, a toxicity report will be submitted per cohort.    A copy of the summary report should be placed in the Principal Investigator’s Regulatory Binder 
under “sponsor correspondence”.  
 
10.0 A
SSESSMENT OF SAFETY  
 10.1 A DVERSE EVENT ASSESSMENT AND REPORTING  
Proprietary Information of MD Anderson
68 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503223] a causal relationship with this treatment. An adverse event can  
therefore be any unfavorable and unintended sign (including an abnormal laboratory  finding, for example), symptom, or disease temporally associated with the use of a  medicinal product or protocol - specified procedure, whether or not considered related to  the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically  significant adverse change in frequency and/or intensity) of a preexisting condition that is  temporally associated with the use of the investigational products is also an adverse  event.  
 Changes resulting from normal growth and development that do not vary significantly in  frequency or severity from expected levels are not to be considered adverse events.  Examples of this may include, but are not limited to, teething, typi[INVESTIGATOR_399236] a physiologically  appropriate time.  
  
Adverse events may occur during clinical trials or as prescribed in clinical practice, from  overdose (whether accidental or intentional), from abuse and from withdrawal.   
Progression of the cancer under study is not considered an adverse event.   
From the time of initial protocol treatment through [ADDRESS_503224]. The reporting timeframe for adverse events meeting  any serious criteria is described in S ection  8.13. The principal investigator [INVESTIGATOR_399237] –serious adverse events for outcome. 
 The principal investigator (or physician designee) is responsible for verifying and providing source documentation for all adverse events and assigning the attribution for all adverse events for subjects enrolled.   An principal investigator [INVESTIGATOR_63124] a qualified physician will evaluate all adverse events   
according to the NCI Common Terminology for Adverse Events (CTCAE), version 5.0. Any adverse event which changes CTCAE grade over the course of a given epi[INVESTIGATOR_399238]/worksheets.  
  
All adverse events regardless of CTCAE grade must also be evaluated for seriousness.  Severity of the adverse events (AEs) - The severity of the adverse events (AEs) will be graded 
according to the National Cancer Institute Common Terminology Criteria for Adverse Events 
(NCI CTCAE) V.5.0.  Events not included in the NCI CTCAE will be scored as follows: 
General grading: 
• Grade 1:  Mild: discomfort present with no disruption of daily activity, no treatment 
required  beyond prophylaxis. 
Proprietary Information of MD Anderson
69 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 • Grade 2:  Moderate: discomfort present with some disruption of daily activity, require 
treatment.  
• Grade 3:  Severe: discomfort that interrupts normal daily activity, not responding to first line 
treatment.  
• Grade 4:  Life Threatening: discomfort that represents immediate risk of death  
 
  
For studies in which multiple agents are administered as part of a combination regimen, the principal investigator [INVESTIGATOR_399239] a single agent of the combination. In general, causality attribution should be assigned to the combination regimen (i.e., to all agents in the regimen). However, causa lity attribution may be 
assigned to a single agent if in the principal investigator’s opi[INVESTIGATOR_1649], there is sufficient data to support full attribution of the adverse experience to the single agent.    All Adverse Events will be reported to regulatory authorities, IRB/IECs     and principal investigators in accordance with all applicable global laws and   regulations.  
Attribution  - the determination of whether an adverse event is related to a medical treatment or 
procedure.  
• Definite  - the adverse event is clearly related to the investigational agent(s).  
• Probable  - the adverse event is likely related to the investigational agent(s). 
• Possible  - the adverse event may be related to the investigational agent(s).  
• Unlikely  - The adverse event is doubtfully related to the investigational agent(s). 
• Unrelated  - The adverse event is clearly NOT related to the investigational agent(s).  
 
 
Recommended Adverse Event Recording Guidelines  
 
Attribution  Grade 1  Grade 2  Grade 3  Grade 4  Grade 5  
Unrelated  Phase I  Phase I  Phase I  
Phase II   
 Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  
Unlikely  Phase I  Phase I  Phase I  
Phase II   Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  
Possible  Phase I  
Phase II   Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  
Probable  Phase I  
Phase II  
 Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  
Proprietary Information of MD Anderson
70 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Definitive  Phase I  
Phase II  
  Phase I  
Phase II   
Phase III  Phase I  
Phase II   
Phase III  Phase I  
Phase II  
Phase III  Phase I  
Phase II   
Phase III  
 
 
 
 10.2 S ERIOUS ADVERSE EVENTS  
   
Serious Adverse Event (SAE) Reporting   An adverse event or suspected adverse reaction is considered “serious” if, in the view of  either the 
principal investigator [INVESTIGATOR_189408], it results in any of the following outcomes: 
 
• Death  
• A life -threatening adverse drug experience – any adverse experience that places the patient, in the 
view of the initial reporter, at immediate risk of death from the adverse experience as it occurred. 
It does not include an adverse experience that, had it occurred in a more severe form, might have caused death.  
• Inpatient hospi[INVESTIGATOR_1081] 
• A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions. 
• A congenital anomaly/birth defect. 
 
Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_3767] a serious adverse drug experience when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse (21 CFR 312.32). 
 
• Important medical events as defined above, may also be considered serious adverse events. Any 
important medical event can and should be reported as an SAE if deemed appropriate by [CONTACT_079] [INVESTIGATOR_9476], IND Office. 
• All events occurring during the conduct of a protocol and meeting the definition of a SAE must be reported to the IRB in accordance with the timeframes and procedures outlined in “The University of [LOCATION_007] M. D. Anderson Cancer Center Institutional Review Board Policy for Investigators on Reporting Serious Unanticipated Adverse Events for Drugs and Devices”.   
• All SAEs, expected or unexpected/ initial or follow up, must be reported to the IND Office within 
5 working days of knowledge of the event  regardless of the attribution.  
• All life -threatening or fatal events,  that are unexpected, and related  to the study drug, must have 
a written report submitted within 24 hours  (next working day) of knowledge of the event to the 
Safety Project Manager in the IND Office.   
• All life -threatening or fatal events , that are unexpected, and related to the study drug, 
must have a written report submitted within 24 hours (next working day) of knowledge of  
Proprietary Information of MD Anderson
71 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503225] Manager in the IND  Office.  
• Unless otherwise noted, the electronic SAE application (eSAE) will be utilized for safety 
reporting to the IND Office and MDACC IRB.  
• The electronic SAE application (eSAE) will be utilized for safety reporting to the IND Office and 
MDACC IRB.  
• Serious adverse events will be captured from the time of the first protocol- specific intervention , 
until [ADDRESS_503226] returned to baseline, progression of the event has stabilized, or there has been acceptable resolution of the event.  
• Additionally, any serious adverse events that occur after the [ADDRESS_503227] be reported to the IND Office. This may 
include the development of a secondary malignancy. 
 Reporting to FDA:  
• Serious adverse events will be forwarded to FDA by [CONTACT_9533] (Safety Project Manager IND Office) according to 21 CFR 312.32. 
 
It is the responsibility of the PI [INVESTIGATOR_180689], Good Clinical Practices, the protocol guidelines, the sponsor’s guidelines, and Institutional Review Board policy.  
 Pregnancy and Reporting  
 If, following initiation of the investigational product, it is subsequently discovered that a study 
subject is pregnant or may have been pregnant at the time of investigational product exposure, 
including during at least [ADDRESS_503228] will 
be permanently discontinued in an appropriate manner (eg, dose tapering if necessary for subject 
safety). The investigator must immediately notify EMD Serono of this event via the Pregnancy 
Surveillance Form in accordance with SAE reporting procedures within [ADDRESS_503229] be reported on the Pregnancy 
Surveillance Form [provided upon request from EMD Serono]. 
 Any pregnancy that occurs in a female partner of a male study participant should be reported to 
EMD Serono. Information on this pregnancy will be collected on the Pregnancy Surveillance 
Form.  
 Reporting Serious Adverse Events and Adverse Events of Special Interest Serious Adverse 
Events  
All events occurring during the conduct of a protocol and meeting the definition of a SAE must 
be reported to the IRB in accordance with the timeframes and procedures outlined in “The 
University of [LOCATION_007] M. D. Anderson Cancer Center Institutional Review Board Policy for 
Investigators on Reporting Serious Unanticipated Adverse Events for Drugs and Devices”.  
Proprietary Information of MD Anderson
72 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503230] be reported to the 
IND Office, regardless of attribution (within 5 working days of knowledge of the event). 
 
SAEs, whether related or not related to study drug as detailed below, must be reported to EMD 
Serono within 5 working days from the time of knowledge of the event to: Pavithra Prasad, Fax: 
[PHONE_3306]; E- mail: [EMAIL_3033] If only limited information is 
initially available, follow -up reports are required. (Note: Follow-up SAE reports should include 
the same investigator term(s) initially reported.)  
 If an ongoing SAE changes in its intensity or relationship to study drug or if new information 
becomes available, a follow -up SAE report should be sent within 5 working days to the EMD 
Serono (or designee) using the same procedure used for transmitting the initial SAE report.  
 All SAEs should be followed to resolution or stabilization. 
 The principal investigato r w
 ill ensure that all SAEs in the clinical database are reported to EMD 
Serono and any applicable health authority during the conduct of the study. 
 SAEs will be reported on the EMD Serono approved form for prompt reporting (full form): 
“Internal SAE Report Form for Prompt Reporting” Institutional Review Board.  
SAEs will be submitted to both the Office of Protocol Research, Unit 1437 at The University of 
[LOCATION_007] MD Anderson Cancer Center and also sent to:
All SAEs should be faxed or e-mailed to EMD  Serono to: 
Fax: [PHONE_3306]; E- mail: [EMAIL_3033]  
 
 10.[ADDRESS_503231] (ECI) and must be reported within 2 working days.    For the time period beginning when the consent form is signed until treatment allocation/randomization, any ECI, or follow up to an ECI, that occurs to any participant  
must be reported within 2 working days if it causes the participant  to be excluded from 
the trial, or is the result of a protocol-specified intervention, including but not limited to washout or discontinuation of usual therapy, diet, placebo treatment or a procedure.  For the time period beginning at treatment allocation/randomization through [ADDRESS_503232] for this trial include: 1.  an overdose of product, as defined in Section 10.4, that is not associated with clinical symptoms or abnormal laboratory results.  2.  an elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of normal and an elevated total bilirubin lab value that is greater than or equal to 2X the 
Proprietary Information of MD Anderson
73 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503233] of protocol-specified laboratory testing or unscheduled laboratory testing.* *Note :  These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require an additional evaluation for an underlying etiology.  In addition, please note that “Events of Clinical Interest” including pregnancy, will be reported via eSAE application as “Other Important Medical Event”, to the IND Office.  
 10.4 D
EFINITION AND REPORTING OF AN OVERDOSE FOR THIS PROTOCOL  
For this study, any dose of bintrafusp alfa greater than 2 times (i.e., > 2400 mg) more than the 
planned dose administered within a 24 -hour time period will be considered an overdose.  
No specific information is available on the treatment of overdose of this drug. In the event of overdose, the participant should be observed closely for signs of toxicity.  Appropriate supportive treatment should be provided if clinically indicated.  If an adverse event(s) is associated with (“results from”) the overdose of a product, the adverse event(s) is reported as a serious adverse event, even if no other seriousness criteria are met.  
 
 10.[ADDRESS_503234] feeding are not considered adverse 
events, it is  the responsibility of principal investigators or their designees to report any 
pregnancy or lactation in a participant (spontaneously reported to them) that occurs during the study. Pregnancies and infant exposures during breastfeeding that occur after the consent form is signed but before treatment allocation/randomization must be reported by [CONTACT_458] [INVESTIGATOR_399240], or are the result of 
a protocol-specified intervention, including but not limited to washout or discontinuation of usual therapy, diet, placebo treatment or a procedure.    Pregnancies and infant exposures during breastfeeding that occur from the time of treatment allocation/randomization through [ADDRESS_503235] be followed to the completion/termination of the pregnancy. Pregnancy outcomes of spontaneous abortion, missed abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage and stillbirth must be reported as serious events (Important Medical Events). If the pregnancy continues to term, the outcome (health of infant) must also be reported. 
11.0 A
DMINISTRATIVE AND REGULATORY DETAILS  
 11.1 I NVESTIGATOR COMMUNICATIONS  
 
Proprietary Information of MD Anderson
74 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503236] be reported within 2 working days to the MDACC IND Office via eSAE application as “Other Important Medical Events.”  
 Additionally, any reportable event, considered by [CONTACT_399283], who is a qualified physician, to be related to product that is brought to the attention of the investigator at any time following consent through the end of the specified safety follow-up period also must be reported.    
 11.2 I
NVESTIGATOR RESPONSIBILITY FOR REPORTING EVENTS  
All Adverse Events will be reported to regulatory authorities and IRB/IECs in accordance 
with all applicable global laws and regulations.  11.[ADDRESS_503237] is completed in a legible and timely manner for every patient enrolled in the study, and that data are recorded on the appropriate forms and in a timely manner in the electronic case report forms (eCRFs) in the Prometheus database. Please note that CORe (Clinical Oncology Research System) will be used to register patients enrolled on the study.  All source documents will be available for inspection by [CONTACT_399284].   
 
  11.3.2 
  DATA SAFETY MONITORING PLAN 
Principal Investigator, Sub-inve stigators, regulatory, CRS  management, c linical re search 
coordina tors, clini cal research a ssociates, da ta manag ers, and c linic staff meet month ly 
to review and discuss study da ta to include, but not li mited t o, the  following: 
• serious adver se events 
• subject safety issues 
• recruitment is sues 
• accrual 
• protocol deviations 
• unantic ipated proble ms 
• breaches of conf identia lity 
Toxicity will be monitored as outlined in the statistical S ection 9.0. All  toxicities 
encount ered during the study w ill be eva luated on an ongoing ba sis according to the 
NCI Common Toxicity Cr iteria version 5. A ll study t reatment a ssociated adv erse 
events that are serious, at l east possibly related and unexpected w ill be reported to the 
IRB. Any modifi cations necessary to ensure subject safety and dec isions to continue, or 
close the trial to accrual are a lso discussed during these m eetin gs. If any literature 
becomes ava ilable whic h changes the r isk/b enefit ratio or sugge sts that conduc ting the 
Proprietary Information of MD Anderson
75 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 trial is no longer ethical, the  IRB w ill be notified in the form of an Unantic ipated 
Problem submission and the study may be t erminated. 
 
For a ll research protoc ols, there will be a c ommitment to comply w ith the IRB’s policies 
for re porting una nticipated problems involving risk to subj ects or other s (including 
adver se events). 
 All records related to this research study w ill be stored in a locked environment. Only 
the res earcher s affiliated with the research study and their staff will have access to the 
research records. 
 
 11.3.[ADDRESS_503238] KEEPI[INVESTIGATOR_399241] (i.e., the study site Investigator ) will maintain records 
in accordance with Good Clinica l Practic e. 
 
The M
DACC inve stigator will retain the MDACC -IND records for [ADDRESS_503239] (IRB)  APPROVAL  
The principal investigator ( i.e., the study site Investigator) w ill obtain, from the MD 
Ander son Can cer Ce nter Institution al Review Board (IRB), prospective approval of the 
clinical protoc ol and corre sponding informed consent form(s); modifications to the 
clinical p rotocol and co rresponding informed c onsent for ms, and adver tisements ( i.e., 
directed at poten tial research subj ects)  for stu dy recruitment, if a pplicable. 
 The only ci rcumstance in which a devia tion from the curre nt IRB-approved c linical 
protocol/consent form( s) may be initiated in the absence of prosp ective  IRB approval 
is to el iminate an appare nt immedia te hazard to the research subj ect(s). I n such 
circumstances,  the principal inve stigator w ill promptly notify the MD  Ander son Cancer 
Center IRB of the deviation.  The MD And ers
on Cancer Center IRB op erates in compliance w ith FDA regulations at 
21 CFR P arts 50 and 21 CFR 56, and in conformance w ith appli cable  International 
Confere nce on Har moni zation (ICH) Guide lines on Good Clini cal P ractice. 
COMPLIANCE WITH TRIAL REGISTRATION AND RESULTS 
POSTING REQUIREMENTS  
Under the terms of the Food and Drug Administration Modernization Act (FDAMA) and the Food and Drug Administration Amendments Act (FDAAA), the Sponsor of the trial is solely responsible for determining whether the trial and its results are subject to the requirements for submission to the Clinical Trials Da ta Bank, 
http://www.clinicaltrials.gov.  Information posted will allow subjects to identify potentially appropriate trials for their disease conditions and pursue participation by [CONTACT_3379] a central contact [CONTACT_57426].  
Proprietary Information of MD Anderson
76 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
   11.3.4    ETHICAL CONSIDERATIONS  
The c linical study w ill be conducted in accordance w ith the curre nt IRB- approved 
clinical p rotocol; I CH Guide lines on Guide lines on G ood Cl inical P ractice; and 
relevant policies, re quirements, and regulations of the Univer sity of [LOCATION_007] MD 
Ander son Cancer Center IRB, and appli cable fe deral agencie s. 
11.3.[ADDRESS_503240] i gator ( i.e., the study site Investigator) w ill make certa in that an appropria te 
informed consent process  is in pl ace to ensure that potentia l research subj ects, or th eir 
authorized representative s, are fully informed about the na ture and obj ectives of the 
clinical study, the pote ntial risks and benef its of study par ticipation, a nd their 
rights a s research subj ects. The investigator, or a sub-inve stigator(s) designated by [CONTACT_399285],  will obta in the wr itten, signed informed consent of each 
subject, or the subj ect’s authorized re presenta tive, prior to p erforming any study-
specific procedu res on the subject. The date a n d time  that the subject, or the subj ect’s 
authori zed re presenta tive, signs the informed consent form and a n arrative of the 
issues discussed during the informed consent process w ill be docume nted in the 
subject’s case history. The inve stigator or sub-inve stigator w ill retain the orig inal copy 
of the signed informed consent for m, and a copy wi ll be provided to the subjec t, or 
to the subj ect’s authorized re presenta tive. 
12.0 S TUDY DOCUMENTATION , MONITORING , AND ADMINISTRATION  
The principal investigator [INVESTIGATOR_399242] (where applicable) 
agrees  to allow the IND Office monitor direct access to all relevant documents and to 
allocate their time and the time to their staff to monitor to discuss findings and any issues.  
 Monitoring visits will be conducted in a manner to ensure that the: 
• Data are authentic, accurate, and complete.  
• Safety and rights of subjects are being protected. 
• Study is conducted in accordance with the currently approved protocol and 
 any other study agreements, ICH GCP, and all applicable regulatory  requirements.  
 
 
   
 
     
Proprietary Information of MD Anderson
77 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
   
 
         
 
         
 
    
APPENDICES  
 
Appendix 1: immunotherapy Response Assessment for Neuro -Oncology (iRANO)  
Modified Excerpt from Original Publication 
Selected sections from the immunotherapy Response Assessment for Neuro-Oncology 
(iRANO), are presented below.  
For the purposes of the current study, we will use a modified version of iRANO (modified iRANO) that allows intracranial tumors that are >0.5 and <1.0 cm assessed by [CONTACT_399286]. This will be the only modification. 
iRANO Criteria  
Proprietary Information of MD Anderson
78 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 The iRANO guidelines incorporate criteria previously deﬁned by [CONTACT_399287]ﬁne complete response, partial response, minor response, stable disease, 
progressive disease, and non- evaluable disease for patients with malignant glioma, 16 
low-grade glioma, 40 and brain metastases. 18 The key component of the iRANO criteria  
is speciﬁc additional guidance for the determination of progressive disease in patients 
with neuro-oncological malignancies undergoing immuno- therapy  (table  1, ﬁgure 3). 
Speciﬁcally,  the iRANO criteria advocate for the conﬁrmation of radiographic progression in 
appropriate patients  deﬁned  by [CONTACT_399288].  
In patients who have imaging ﬁndings that meet RANO  criteria for progressive disease 16–
[ADDRESS_503241] 
identiﬁed  (table  1). Patients  who develop substantial new or worsened neurological deﬁcits 
not due to comorbid events or a change  in co-administered  medication  at any time within 
the 3 -month follow-up window should be designated as non-responsive to treatment and 
should discontinue immunotherapy. For these patients,  the date of actual tumor 
progression should also be back-dated to the date when radiographic progressive disease was 
initially identiﬁed . 
 
RANO and iRANO criteria (Brain Metastases)  
 Brain metastases  
COMPLETE 
TARGET  Disappearance of all enhancing target and non -lesions for ≥4 
weeks; no new lesions; no steroids; clinically stable or improved 
PARTIAL 
RESPONSE  ≥30%  decrease  in sum of longest  diameters  of target lesions  for ≥4 
weeks;  no new lesions;  stable  or decreased steroid  dose;  clinically  
stable  or improved  
MINOR RESPONSE  NA 
STABLE DISEASE  Does not qualify for complete response, partial response, or 
progressive disease 
Proprietary Information of MD Anderson
79 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 PROGRESSIVE 
DISEASE  ≥20% increase in the sum of longest diameters of target lesions; 
or unequivocal progression of enhancing non- target lesions; or 
new lesions; or substantial clinical decline  
The iRANO criteria integrate into the existing RANO criteria for malignant glioma, 
low-grade glioma, and brain metastases by [CONTACT_399289]. Speciﬁcally,  iRANO recommends  
conﬁrmation  of disease  progression  on follow -up imaging 3 months  after initial radiographic  
progression  if there  is no new or substantially  worsened  neurological  deﬁcits  that are not due 
to comorbid events  or concurrent  medication,  and it is 6 months or less from  starting  
immunotherapy. If follow-up imaging  conﬁrms  disease progression, the date of actual  
progression should be back -dated  to the date of initial radiographic progression. The 
appearance of new lesions  6 months or less from  the initia tion of immunotherapy alone 
does not deﬁne  progressive disease.  FLAIR=ﬂuid -attenuated  inversion recovery.  
iRANO= immunotherapy Response Assessment in Neuro -Oncology.  N/A=not  applicable.  
 
     
 
Proprietary Information of MD Anderson
80 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 If radiographic ﬁndings at the 3-month follow-up meet RANO criteria for stable disease, 
partial response, or complete response 16–[ADDRESS_503242] 
integrated guidance from the immune -
related response criteria regarding interpretation of progressive imaging findings with existing RANO criteria to form the iRANO guidelines. A comparison of the key features associated with RANO, immune -
related response criteria, and iRANO are summarized (table 2). Although application of immunotherapi[INVESTIGATOR_399243]-oncology malignancies is in the early stages of development and much remains to be learned, the iRANO criteria provides guidelines that can be applied to provide consistent metrics in clinical trials and daily practice. Particularly, these guidelines shall raise awareness of the possibility of potentially misleading early progressive radiographic changes after initiation of immunotherapy, and provide guidance for responding to these changes to decrease the likelihood of inappropriate 
Yes 
 No 
>6 months  
 ≤6 months  
as long as no signiﬁcant clinical decline 
unrelated to 
Repeat imaging 3 months after initial imaging 
 
Discontinue current  
 
Patient classiﬁed as having progressive Figure a: iRANO treatment algorithm for the assessment of progressive imaging ﬁndings in patients with 
neuro -oncological malignancies undergoing immunotherapy  
Proprietary Information of MD Anderson
81 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version [ADDRESS_503243] the iRANO guidelines will be amended 
successively to improve their usefulness as further experience and systematic data from continuing immunotherapy trials in neuro-oncology accumulate. 
Key Considerations for RANO Criteria, Immune- Related Response Criteria, and 
iRANO Criteria  
 
 RANO  Immune -
related 
response 
criteria  iRANO (if 
therapy ≤6 
months after 
start of 
immunotherapy  iRANO (if >6 
months after 
start of 
immunotherapy)  
Is a repeat scan needed 
to conﬁrm 
radiographic 
progressive disease for 
patients without 
signiﬁcant clinical 
decline?  No Yes Yes No 
Minimum time interval 
for conﬁrmation of disease progression for patients without signiﬁcant clinical decline  
 NA ≥ 4 weeks  ≥ 3 months  NA 
Is further  
immunotherapy  
treatment  allowed  after  
initial  radiographic  
progressive  disease  (if 
clinically  stable)  
pending disease  
progression  
conﬁrmation?  
 NA YES  Yes NA 
Does a new lesion deﬁne progressive disease?  
 Yes No No Yes 
 iRANO=immunotherapy Response Assessment in Neuro -Oncology. N/A=not applicable.  
 
  
 
Proprietary Information of MD Anderson
82 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Appendix 2  
 
 Response Evaluation Criteria in Solid Tumors (RECIST v1.1 Criteria) The RECIST criteria should be used to assess response to treatment. Only patients with measurable disease should be entered in the study. Measurable extracranial disease is defined as the presence of one lesion that can be accurately measured in at least one 
dimension (longest diameter to be recorded) as ≥2.0 cm with conventional techniques (or 
as ≥1.[ADDRESS_503244]). Evaluable lesions should be followed for the assessment of 
response. Non- measurable lesions  include bone lesions, ascites, pleural/pericardial 
effusion, lymphangitic carcinomatosis, abdominal masses that are not confirmed by C T, 
and cystic lesions. Disease progression and response evaluations for intracranial and 
extracranial disease will be determined according to the definitions established in the Response Evaluation Criteria in Solid Tumours (RECIST v1.1). Minor modifications will be applied to the assessment of intracranial lesions:  
• General: target lesions should be representative of the subject’s baseline tumor burden 
and should be selected based on their size (i.e. lesions with the longest diameter) and their suitability for accurate repeat assessment.  
• Intracranial lesions: (the modifications to RECIST v1.1. impact the number and the minimal size of the target lesions selected at baseline) up to five lesions should be selected as target lesions; all brain lesions in excess of these five target lesions have to be regarded as non -target lesions. Measurable lesions are defined as those that can be 
accurately measured in at least one dimension with the longest diameter ≥ [ADDRESS_503245] -enhanced MRI is the only imaging 
modality accepted for assessment of intracranial lesions.  
• Extracranial lesions: up to two lesions per organ representative of all involved organs should be selected as target lesions; the total number of target lesions should not exceed five and all lesions in excess of these five target lesions have to be regard ed as non-
target lesions.  
 
Baseline Documentation of Intracranial Target and Non- Target Lesions  
• All baseline lesion assessments must be performed within [ADDRESS_503246] dose of study treatment.  
• Measurable and non-measurable intracranial (i.e. brain parenchyma) lesions up to a maximum of 5 lesions should be identified as target lesions, and recorded and measured at baseline. These lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by [CONTACT_14217]). 
• Cystic lesions thought to represent cystic metastases should not be selected as target lesions when other suitable target lesions are available.  
• Measurable intracranial lesions that have been previously irradiated and have not been shown to be progressing following irradiation should not be considered as target 
Proprietary Information of MD Anderson
83 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 lesions. All other intracranial lesions should be identified as non-target and should 
also be recorded at baseline. Measurements of non-target lesions are not required, but the presence or absence of each should be noted throughout follow-up. 
Baselin e Documentation of Extracranial Target and Non- Target Lesions  
• All baseline lesion assessments must be performed within [ADDRESS_503247] dose of study treatment.  
• Lymph nodes that have a short axis of <10mm are considered non -pathological and 
should not be recorded or followed. 
• Pathological lymph nodes with <15mm and ≥10mm short axis are considered non measurable.  
• Pathological lymph nodes with ≥15mm short axis are considered measurable and can be selected as target lesions, however lymph nodes should not be selected as target lesions when other suitable target lesions are available.  
• Measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, representative of all involved extracranial organs, should be identified as target lesions, and recorded and measured at baseline. These lesions should be selected on the bas is 
of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by [CONTACT_14217]).  
• Cystic lesions thought to represent cystic metastases should not be selected as target lesions when other suitable target lesions are available.  
• Measurable extracranial lesions that have been previously irradiated and have not been shown to be progressing following irradiation should not be considered as target lesions.  
• Lytic bone lesions or mixed lytic -blastic lesions, with identifiable soft tissue 
components, that can be evaluated by [CONTACT_399290]. 
• Bone scans, FDG -PET scans or X -rays are not considered adequate imaging techniques 
to measure bone lesions. 
• All other lesions (or sites of disease, excluding the brain) should be identified as non-target and should also be recorded at baseline. 
• Non-target lesions will be grouped by [CONTACT_90628]. Measurements of these lesions are not 
required, but the presence or absence of each should be noted throughout follow-up. 
Overall Intracranial Response - Evaluation of Intracranial Target Lesions 
Definitions for assessment of response for intracranial target lesion(s) are as follows: 
• Complete Response (CR): Disappearance of all target lesions.  
• Partial Response (PR): At least a 30% decrease in the sum of the diameters of target 
lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).  
• Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.  
Proprietary Information of MD Anderson
84 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 • Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target 
lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm. 
• Not Evaluable (NE): Cannot be classified by [CONTACT_91076]. 
Note: If an intracranial target lesion disappears and reappears at a subsequent time point it should continue to be measured. The response at the time when the lesion reappears will depend upon the status of the other lesions. For example, if the disease h ad reached a CR status then PD would be documented at the time of 
reappearance. However, if the response status was PR or SD, the diameter of the reappearing lesion should be added to the remaining diameters and response determined based on percent change from baseline and percent change from nadir.  
• Patients, who in the opi[INVESTIGATOR_399244] a substantial decline in their performance status and have clinical evidence of progressive disease may be classified as having progressive disease.  
 
 
Appendix 2: Current National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCI CTCAE Version 5.0) 
 
Please use the following link to the NCI CTCAE website: 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  
 
  
Proprietary Information of MD Anderson
85 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Appendix 3: Eastern Cooperative Oncology Group (ECOG) Performance Status 
Scale 
 
Grade  Description  
0 Fully active, able to carry on all pre -disease performance without 
restriction  
1 Restricted in physically strenuous activity but ambulatory and able to 
carry out wo rk of a light or sedentary nature, e.g., light housework or 
office work  
2 Ambulatory and capable of all self -care but unable to carry out any work 
activities; up and about >  50% of waking hours 
3 Capable of only limited self -care, confined to a bed or ch air > 50% of 
waking hours 
4 Completely disabled; cannot carry on any self-care; totally confined to 
bed or chair  
5 Dead  
 
  
Proprietary Information of MD Anderson
86 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 Appendix 4: Contraceptive Guidance and Pregnancy Testing  
Woman of Childbearing Potential (WOCBP) 
A woman is considered fertile following menarche and until becoming post-menopausal unless permanently sterile (see below)  
Women in the following categories are not considered WOCBP: 
• Pre-menarchal  
• Premenopausal female with 1 of the following: 
• Documented hysterectomy  
•  Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy 
Note:  Documentation can come from the site personnel’s review of the participant’s medical records, medical examination, or medical history interview.  
• Postmenopausal female  
• A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.  
o A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with two FSH measurements in the postmenopausal range is required.  
 
• Females on HRT and whose menopausal status is in doubt will be required to use 
one of the non-hormonal highly effective contraception methods if they wish to 
continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment. 
 
C
ONTRACEPTION REQUIREMENTS  
Male Participants:  
Male participants with female partners of childbearing potential are eligible to participate 
if they agree to one of the following during the protocol as defined :  
● Be abstinent from penile-vaginal intercourse as their usual and preferred lifestyle 
(abstinent on a long term and persistent basis) and agree to remain abstinent 
● Use a male condom plus partner use of a contraceptive method with a failure rate of 
<1%  per year as described in Table 5 when having penile-vaginal intercourse with a 
woman of childbearing potential who is not currently pregnant. 
○ Note: Men with a pregnant or breastfeeding partner must agree t o  remain 
abstinent from penile-vaginal intercourse or use a male condom during each 
epi[INVESTIGATOR_117492]. 
 
Ta
ble 2: Highly Effective Contraceptive Methods That Have Low User Dependency  
Highly Effective Methods That Have Lo w User Dependency  
Failure rate of <1% per year when used consistently and correctly.  
● Progestogen - only contraceptive implant a, b 
● Intrauterine hormone- releasing system (IUS) b 
● Intrauterine device (IUD)  
Proprietary Information of MD Anderson
87 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 ● Bilateral tubal occlusion  
 
● Vasectomized partner  
A vasectomized partner is a highly effective contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been 
confirmed. If not, an additional highly effective method of contraception sho uld be used.  
● Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining 
from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstin ence needs to be evaluated in relation to the 
duration of the study and the preferred a nd usual lifestyle of the participant.  
Notes:  
Use should be consistent with local regulations regarding the use of contraceptive methods 
for participants of clinical s tudies. 
 a) If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) 
guidelines, acceptable contraceptive implants are limited to those which inhibit ovulation. 
b) If hormonal contraception efficacy is potentially decreased due to interaction with study 
treatment, condoms must be used in addition to the hormonal contraception during the treatment period and for at least 120 days, corresponding to time needed to eliminate study treatment plus 30 days for study treatments with genotoxic potential]  after the last dose of 
study treatment.   
  Female Participants:  
Female participants of childbearing potential are eligible to participate if they  agree to 
use a highly effective method of contraception consistently and correctly as described in Table 6 during the protocol- defined time frame .   
 Table 3: Highly Effective Contraception Methods  
Highly Effective Co ntraceptive Methods That Are User Dependent a  
Failure rate of <1% per year when used consistently and correctly.  
● Combined (estrogen - and progestogen - containing ) hormonal contraception b, c 
○ Oral  
○ Intravaginal  
○ Transdermal  
○ Injectable  
● Progestogen -only hormonal contraception b, c 
○ Oral  
○ Injectable  
Highly Effective Methods That Have Low User Dependency  
Failure rate of <1% per year when used consistently and correctly.  
● Progestogen - only contraceptive implant b, c  
● Intrauterine hormone- releasing system (IUS) b  
● Intrauterine device (IUD)  
● Bilateral tubal occlusion  
Proprietary Information of MD Anderson
88 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
● Vasectomized partner  
A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be used.  
● Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the 
study and the preferred and usual lifestyle of the participant.)  
Notes:  
Use should be consistent with local regulations regarding the use of contraceptive methods for 
participants of clinical studies.  
 a) Typi[INVESTIGATOR_122955] -use failure rates (i.e. when used consistently 
and correctly).  
b) If hormonal contraception efficacy is potentially decreased due to interaction with study 
treatment, condoms must be used in addition to the hormonal contraception during the treatment period and for at least  120 days, corresponding to time needed to eliminate study 
treatment plus 30 days for study treatments with genotoxic potential]  after the last dose of study treatment .  
c) If locally requ ired, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, 
acceptable hormonal contraceptives are limited to those which inhibit ovulation.  
 P
REGNANCY TESTING  
WOCBP should only be included after a negative highly sensitive urine or serum pregnancy test and in accordance with local requirements.  When applicable, this test should be repeated a maximum of 24-hours before the first dose/vaccination. Following initiation of treatment additional pregnancy testing will be performe d at Day [ADDRESS_503248] dose of study treatment and as required locally.  Pregnancy testing will be performed whenever an expected menstrual cycle is missed or when pregnancy is otherwise suspected.  
            
Proprietary Information of MD Anderson
89 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
Appendix 6  NCCN GUIDELINES FOR TREATMENT OF CANCER  
   https://www.nccn.org/professionals/physician_gls/default.aspx  
    Appendix 7   AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLICINAL PRACTICE GUIDELINES  
  https://www.asco.org/practice- guidelines/quality -guidelines/guidelines  
                          
Proprietary Information of MD Anderson
90 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
Appendix 8   Neurologic Assessment in Neuro -Oncology (NANO) Scale  
 Scoring assessment is based on direct observation and testing performed during clinical evaluation and is not based on historical information or reported symptoms. Please check one answer per domain. Please check “Not assessed” if testing for that domain i s not 
done. Please check “Not evaluable” if a given domain cannot be scored accurately because of preexisting conditions, comorbid events, or concurrent medications.   
Patient identifier:                      Date assessment performed (day/month/year):                                                                            
Study time point (ie, baseline, cycle 1, day 1, etc):     
Assessment performed by (please print name):      
 Domains Key Considerations   Gait 
0 Normal  
1 Abnormal but walks without assistance 2 Abnormal and requires assistance (companion, cane, walker, etc.) [ADDRESS_503249] resistance  
3 No movement Not assessed Not evaluable    Ataxia (Upper Extremity)  
0 Able to finger- to-nose touch without difficulty 
1 Able to finger- to-nose touch but difficult 
2 Unable to finger- to-nose touch Not assessed 
Not evaluable   Sensation  
0 Normal  
1 Decreased but aware of sensory modality  
2 Unaware of sensory modality Not assessed Not evaluable  
Proprietary Information of MD Anderson
91 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
Visual Fields  
0 Normal  
1 Inconsistent or equivocal partial hemianopsia (≥quadrantanopsia)  
2 Consistent or unequivocal partial hemianopsia (≥quadrantanopsia)  
3 Complete hemianopsia Not assessed  
Not evaluable   Facial Strength  
0 Normal  
1 Mild/moderate weakness  
2 Severe facial weakness Not assessed  
Not evaluable    Language 0 Normal  
1 Abnormal but easily conveys meaning to examiner  
2 Abnormal and difficulty conveying meaning to examiner 3 Abnormal; if verbal, unable to convey meaning to examiner; OR nonverbal (mute/global aphasia) Not assessed Not evaluable   Level of Consciousness 0 Normal  
1 Drowsy (easily arousable) 2 Somnolent (difficult to arouse) 3 Unarousable/coma Not assessed  
Not evaluable   Behavior 0 Normal  
1 Mild/moderate alteration  
2 Severe alteration Not assessed Not evaluable  
         
Proprietary Information of MD Anderson
92 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
 Appendix 9  Assessment of Quality of Life (QOL)  
 https://www.aqol.com.au/documents/AQoL-8/AQoL-8_questionnaire.pdf  
                                     Appendix 10   Pi[INVESTIGATOR_399245]
93 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
 Pi[INVESTIGATOR_399246]:Min  
00:00-
23:59  Dose  
 
 
mg Time 
of 
Dose  
Hr:Min  
00:00-
23:59  Dose  
 
 
mg Patient comments for side 
effects related to drugs  
e.g., 06 
JAN 11  07:30  60 18:15  60 Nausea  
1.      
2.      
3.      
4.      
5.      
6.      
7.      
8.      
9.      
10.      
11.      
12.      
13.      
14.      
15.      
16.      
17.      
18.      
19.      
      
      
 
 Pi[INVESTIGATOR_399247]
94 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
  
Patient Signature: ____________________________  Date: ___________________  
 
The Physician’s Office will complete this section:  
 
1. Start date: ____________________                   End date:  
___________________________  
2. Total number of pi[INVESTIGATOR_399248]:_____________________________________  
3. Total number of pi[INVESTIGATOR_399249]: 
________________________________________  
4. Total number of pi[INVESTIGATOR_399250]:______________________________________  
 
Physician/Nurse 
Signature:________________________________________________________  
 
 
Comments:_________________________________________________________________
____  
 Date 
of 
Dose  
 
 
 
Day Month 
Year  Time 
of 
Dose  
Hr:Min  
00:00-
23:59  Dose  
 
 
mg Time 
of 
Dose  
Hr:Min  
00:00-
23:59  Dose  
 
 
mg Patient comments for side 
effects related to drugs  
e.g.,  06 
JAN 11  07:30  60 18:15  60 Nausea  
21.      
22.      
23.      
24.      
25.      
26.      
27.      
28.      
29.      
30.      
Proprietary Information of MD Anderson
95 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 13.0 R EFERENCES  
 
1.  Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases 
treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised 
controlled trial.  Lancet Oncol. 2009;10: 1037-1044.  
2. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain 
radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a 
randomized controlled trial. JAMA. 2006;295: 2483-2491.  
3. Disis ML. Immune regulation of cancer. J Clin Oncol. 2010;28: 4531-4538. 
4. Geller, A.C., et al., Melanoma incidence and mortality among US whites, 1969-1999. 
Jama, 2002. 288(14): p. 1719-[ADDRESS_503250] -Line  Nivolumab (NIVO; Anti-Programmed 
Death -1 [PD -1]) and Ipi[INVESTIGATOR_222102]- Small Cell Lung Cancer (NSCLC).  World Lung 
Conference. Denver, CO, 2015.  6.
 Blank, C. and A. Mackensen, Contribution of the PD- L1/PD -[ADDRESS_503251] to T- cell 
exhaustion: an update on implications for chronic infections and tumor evasion. Cancer 
Immunol Immunother, 2007. 56(5): p. 739-45. 
7. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced 
Squamous- Cell Non -Small- Cell Lung Cancer.  N Engl J Med. 2015;373: 123-135. 
8. Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, Burger P, Rumizen MJ, Podar 
K, Chauhan D, Hideshima T, Munshi NC, Richardson P, Clark A, Ogden J, Goutopoulos 
A, Rastelli L, Anderson KC, Tai YT. Blockade of the MEK/ERK signalling cascade by 
[CONTACT_113879]703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti- myeloma 
activity in vitro and in vivo. Br J Haematol. 2010;149(4):537–549. doi: 10.1111/j.1365-
2141.2010.[ZIP_CODE].x. 9. Hoos A. Evolution of end points for cancer immunology trials.  Ann Oncol. 2012.[ADDRESS_503252] 8:  viii47-52 10. Hui, E., et al., T cell costimulatory receptor CD28 is a primary target for PD -1-
  
mediated inhibition . Science, 2017. 355(6332): p. 1428-1433. 
11. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for 
melanoma brain metastases in the ipi[INVESTIGATOR_399251].  J 
Neurosurg. 2012;117: 227-233. 
12. Shoukat S, Marcus MM, Rizzo M, et al. Outcome with stereotactic radiosurgery 
(SRS) and ipi[INVESTIGATOR_125] (Ipi) for malignant melanoma brain metastases (mets).  J Clin 
Oncol. 2014;32 13. Kiess AP, Wolchok JD, Barker CA, et al. Stereotactic radiosurgery for melanoma 
brain metastases in patients receiving ipi[INVESTIGATOR_125]: safety profile and efficacy of 
combined treatment.  Int J Radiat Oncol Biol Phys. 2015;92: 368-375. 
14. Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) 
of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non- SQ) 
non-small cell lung cancer (NSCLC).  Journal of Clinical Oncology. 2015;33. 
15.  Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipi[INVESTIGATOR_53906]-
line treatment for advanced non- small-cell lung cancer (CheckMate 012): results of an 
open-label, phase 1, multicohort study. Lancet Oncol. 2017;18: 31-41. {21} 
16.  Kopf, A.W., D.S. Rigel, and R.J. Friedman, The rising incidence and mortality rate  
of malignant melanoma.  J Dermatol Surg Oncol, 1982. 8(9): p. 760-1.  
Proprietary Information of MD Anderson
96 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 17. Jemal, A., et al., Global cancer statistics . CA Cancer J Clin, 2011. 61(2): p. 69-90. 
18. Alexandru, D., D.A. Bota, and M.E. Linskey, Epi[INVESTIGATOR_399252].  Prog Neurol Surg, 2012. 25: p. 13-29. 
19. Antonadou, D., et al., Phase II randomized trial of temozolomide and concurrent  
radiotherapy in patients with brain metastases.  J Clin Oncol, 2002. 20(17): p. 3644-50. 
20. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll 
or Hyde. Cancer Metastasis Rev. 2007;26: 373-400. 
21. Rigel, D.S., J. Russak, and R. Friedman, The evolution of melanoma diagnosis: 25  
years beyond the ABCDs . CA Cancer J Clin, 2010. 60(5): p. 301-16.  
22. Geller, A.C., et al., Melanoma incidence and mortality among US whites, 1969-1999.  
Jama, 2002. 288(14): p. 1719-20. 23. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics , 2004. CA
  Cancer J Clin. 
2004;54: 8-29. 2015-0883 Version 7 Page 61  24. Peto R, Lopez AD, Boreham J, Thun M, Heath C, Jr. Mortality from tobacco in 
developed countries: indirect estimation from national vital statistics.  Lancet. 1992;339: 
1268-1278.  25. Patchell RA. Handbook of neurology. 1997. 
26. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain 
metastases treated with radiosurgery or radiosurgery plus whole- brain irradiation: a 
randomised controlled trial. Lancet Oncol. 2009;10: 1037-1044. 
27.  Arrieta, O., et al., Long -term survival in patients with non -small cell lung cancer and 
synchronous brain metastasis treated with whole-brain radiotherapy and thoracic 
chemoradiation. Radiat Oncol, 2011. 6: p. 166. 
28. Munn, D.H. and A.L. Mellor, Indoleamine 2,3-dioxygenase and tumor-induced  
tolerance.  J Clin Invest, 2007. 117(5): p. 1147-54. 
29. Ann W. Silk, Yue Cao, Diana Gomez- Hassan, Bruce G. Redman, James Hayman, 
Jason Heth, and Christopher D. Lao.  A randomized phase II study of ipi[INVESTIGATOR_399253].  
Journal of Clinical Oncology 2015 33:15_suppl, TPS9079-TPS9079  30. Hiraoka N. Tumor -infiltr
 ating lymphocytes and hepatocellular carcinoma: molecular 
biology. Int J Clin Oncol. 2010;15: 544-551.  
31. Nobili C, Degrate L, Caprotti R, et al. Prolonged survival of a patient affected by 
[CONTACT_80099] -2 immunotherapy. Report of a case. Tumori. 2008;94: 426-430.  
32. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and Ipi[INVESTIGATOR_399254].  N Engl J Med. 2015.  
33. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipi[INVESTIGATOR_195709].  N Engl J Med. 2013;369: 122-133.  
34. Twyman- Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint 
blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520: 373-
377.  35. Hodi FS, O'Day SJ, McDermott DF, et al. Impr
 oved survival with ipi[INVESTIGATOR_362].  N Engl J Med. 2010;363: 711-723. 
36. Aoyama H, Tago M, Kato N, et al. Neurocognitive function of patients with brain 
metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or 
radiosurgery alone. Int J Radiat Oncol Biol Phys. 2007;68: 1388-1395.  
Proprietary Information of MD Anderson
97 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 37. DeAngelis LM, Delattre JY, Posner JB. Radiation -induced dementia in patients cured 
of brain metastases. Neurology. 1989;39: 789-796.  
38. Shapi[INVESTIGATOR_35926], Benedict RH, Schretlen D, Brandt J. Construct and concurrent validity 
of the Hopkins Verbal Learning Test- revised.  Clin Neuropsychol. 1999;13: 348-358.  
39. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non- sma ll-cell 
lung cancer. N Engl J Med. 2015;372: 2018-2028.  
40. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator- choice 
chemotherapy for ipi[INVESTIGATOR_125]- refractory melanoma (KEYNOTE -002): a randomised, 
controlled, phase 2 trial. Lancet Oncol. 2015.  
41. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipi[INVESTIGATOR_399255].  N Engl J Med. 2015;372: 2521-2532.  
36. Okada H, Weller M, Huang R, et al. Immunotherapy response assessment in neuro-
oncology: a report of the RANO working group. Lancet Oncol. 2015;16: e534-542. 
42. Hoos A. Evolution of end points for cancer immunotherapy trials. Ann Oncol. 
2012;[ADDRESS_503253] 8: viii47-52.  
43. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti -
PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515: 563-567. 2015-0883 
Version 7 Page 63  44. Shaw E, Scott C, Souhami L, et al. Radiosurgery for the treatment of previously 
irradiated recurrent primary brain tumors and brain metastases: initial report of radiation 
therapy oncology group protocol (90-05). Int J Radiat Oncol Biol Phys. 1996;34: 647-
654. 45. Margolin K, Ernstoff MS, Hamid O, et al. Ipi[INVESTIGATOR_399256]: an open -label, phase 2 trial. Lancet Oncol. 2012;13: 459-465.  
46. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-
programmed death- 1 (MDX -1106) in refractory solid tumors: safety, clinical activity, 
pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28: 3167-3175. 
47. Yoon J, Koo KH, Choi KY. MEK1/2 inhibitors AS703026 and AZD6244 may be 
potential therapi[INVESTIGATOR_399257]. Cancer Res. 2011;71(2):445–453 
48. Park SJ, Hong SW, Moon JH, Jin DH, Kim JS, Lee CK, Kim KP, Hong YS, Choi EK, Lee JS, Lee JL, Kim TW. The MEK1/2 inhibitor AS703026 circumvents resistance 
to the BRAF inhibitor PLX4032 in human malignant melanoma cells. Am J Med Sci. 
2013;346(6):494–[ADDRESS_503254] R, Rejeb N, Raymond E. Safety and recommended phase II dose (RP2D) of the 
selective oral MEK1/2 inhibitor pi[INVESTIGATOR_399163] (MSC1936369B/AS703026): Results of a 
phase I trial [Abstract]  Eur J Cancer. 2012;48:185–186. Abstr 604.  
50. Macarulla T, Cervantes A, Tabernero J, Rosello S, Van Cutsem E, Tejpar S, Prenen 
H, Martinelli E, Troiani T, Laffranchi B, Jego V, von Richter O, Ciardiello F. Phase I 
study of FOLFIRI plus pi[INVESTIGATOR_399258]- line treatment for KRAS -mutated metastatic 
colorectal cancer. Br J Cancer. 2015;112(12):1874–1881 
51.  Ebert et al. MAP Kinase Inhibition Promotes T Cell and Anti- tumor Activity in 
Combination with PD-L1 Checkpoint Blockade. Immunity.  2016 Mar 15;44(3):609-621.  
52. Loi et al. RAS/MAPK Activation Is Associated with Reduced Tumor- Infiltrating 
Lymphocytes in Triple- Negative Breast Cancer: Therapeutic Cooperation Between MEK 
Proprietary Information of MD Anderson
98 
BINTRAFUSP ALFA (M7824)+Pi[INVESTIGATOR_399159]  
2019- 1091, Version 5 
 and PD-1/PD- L1 Immune Checkpoint Inhibitors. Clin Cancer Res.  2016 Mar 
15;22(6):1499-509 
53. Tawbi et al. Combined Nivolumab and Ipi[INVESTIGATOR_399259]. N Engl J Med 2018; 379:722-730 
54. Davies et al.  Dabrafenib plus trametinib in patients with BRAF V600–mutant 
melanoma brain metastases (COMBI -MB): a multi-cohort, open- label, phase 2 trial.   
Lancet Oncol. 2017 Jul; 18(7): 863–873. 55.  Chang et al. Neurocognition in patients with brain metastases treated with 
radiosurgery or radiosurgery plus whole- brain irradiation: a randomised controlled trial.   
Lancet Oncol. 2009 Nov;10(11):1037-44 56.  Robert et al.  Pembrolizumab versus ipi[INVESTIGATOR_15172] 
(KEYNOTE -006): post-hoc 5-year results from an open-label, multicentre, randomised, 
controlled, phase 3 study. Lancet Oncol. 2019 Jul 22 10(16): 1470-2045 
57.  Moya Horno et al. Combination of immunotherapy with targeted therapi[INVESTIGATOR_399260]- small cell lung cancer (NSCLC).   The Adv Med Oncol. 2018 Jan 9: 17-25 
58. Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, 
Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, 
Ciardiello F; IMblaze370 Investigators. Atezolizumab with or without cobimetinib versus 
regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a 
multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019 
Jun;20(6):849-861.      
Proprietary Information of MD Anderson